<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80229</article-id><article-id pub-id-type="doi">10.7554/eLife.80229</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Characterization of full-length <italic>CNBP</italic> expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-282081"><name><surname>Alfano</surname><given-names>Massimiliano</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-282082"><name><surname>De Antoni</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282083"><name><surname>Centofanti</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282084"><name><surname>Visconti</surname><given-names>Virginia Veronica</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282085"><name><surname>Maestri</surname><given-names>Simone</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1192-0684</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282086"><name><surname>Degli Esposti</surname><given-names>Chiara</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5974-4915</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282087"><name><surname>Massa</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282088"><name><surname>D'Apice</surname><given-names>Maria Rosaria</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208421"><name><surname>Novelli</surname><given-names>Giuseppe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7781-602X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-186594"><name><surname>Delledonne</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-282089"><name><surname>Botta</surname><given-names>Annalisa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4031-5624</contrib-id><email>botta@med.uniroma2.it</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-279604"><name><surname>Rossato</surname><given-names>Marzia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6101-1550</contrib-id><email>marzia.rossato@univr.it</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/039bp8j42</institution-id><institution>Department of Biotechnology, University of Verona</institution></institution-wrap><addr-line><named-content content-type="city">Verona</named-content></addr-line><country>Italy</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02p77k626</institution-id><institution>Department of Biomedicine and Prevention, Medical Genetics Section, University of Rome Tor Vergata</institution></institution-wrap><addr-line><named-content content-type="city">Rome</named-content></addr-line><country>Italy</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02p77k626</institution-id><institution>Department of Systems Medicine (Neurology), University of Rome Tor Vergata</institution></institution-wrap><addr-line><named-content content-type="city">Rome</named-content></addr-line><country>Italy</country></aff><aff id="aff4"><label>4</label><institution>Laboratory of Medical Genetics, Tor Vergata Hospital</institution><addr-line><named-content content-type="city">Rome</named-content></addr-line><country>Italy</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cpb6264</institution-id><institution>IRCCS Neuromed, Via Atinense</institution></institution-wrap><addr-line><named-content content-type="city">Molise</named-content></addr-line><country>Italy</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01keh0577</institution-id><institution>Department of Pharmacology, School of Medicine, University of Nevada Reno</institution></institution-wrap><addr-line><named-content content-type="city">Reno</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Genartis s.r.l., Via P. Mascagni</institution><addr-line><named-content content-type="city">Castel D'azzano</named-content></addr-line><country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Pollak</surname><given-names>Martin R</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard Medical School</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>26</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e80229</elocation-id><history><date date-type="received" iso-8601-date="2022-05-12"><day>12</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-25"><day>25</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-05-12"><day>12</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.12.491603"/></event></pub-history><permissions><copyright-statement>© 2022, Alfano, De Antoni et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Alfano, De Antoni et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80229-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80229-figures-v2.pdf"/><abstract><p>Myotonic dystrophy type 2 (DM2) is caused by CCTG repeat expansions in the <italic>CNBP</italic> gene, comprising 75 to &gt;11,000 units and featuring extensive mosaicism, making it challenging to sequence fully expanded alleles. To overcome these limitations, we used PCR-free Cas9-mediated nanopore sequencing to characterize <italic>CNBP</italic> repeat expansions at the single-nucleotide level in nine DM2 patients. The length of normal and expanded alleles can be assessed precisely using this strategy, agreeing with traditional methods, and revealing the degree of mosaicism. We also sequenced an entire ~50 kbp expansion, which has not been achieved previously for DM2 or any other repeat-expansion disorders. Our approach precisely counted the repeats and identified the repeat pattern for both short interrupted and uninterrupted alleles. Interestingly, in the expanded alleles, only two DM2 samples featured the expected pure CCTG repeat pattern, while the other seven presented also TCTG blocks at the 3′ end, which have not been reported before in DM2 patients, but confirmed hereby with orthogonal methods. The demonstrated approach simultaneously determines repeat length, structure/motif, and the extent of somatic mosaicism, promising to improve the molecular diagnosis of DM2 and achieve more accurate genotype–phenotype correlations for the better stratification of DM2 patients in clinical trials.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>myotonic dystrophy type 2</kwd><kwd><italic>CNBP</italic> gene</kwd><kwd>repeat expansion</kwd><kwd>Cas9-mediated enrichment</kwd><kwd>nanopore sequencing</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005202</institution-id><institution>Muscular Dystrophy Association</institution></institution-wrap></funding-source><award-id>MDA 876149</award-id><principal-award-recipient><name><surname>Delledonne</surname><given-names>Massimo</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Italian DiMio onlus association of DM patients (www.dimio.it)</institution></institution-wrap></funding-source><award-id>volunteer donation</award-id><principal-award-recipient><name><surname>Botta</surname><given-names>Annalisa</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel sequencing-based method to characterize CNBP microsatellite expansions in DM2 patients demonstrates benefits for an improved dissection of DM2 genetic architecture, thus potentially ameliorating patient stratification and genetic counseling.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Myotonic dystrophy type 2 (DM2; MIM#602668) is an autosomal dominant multisystem disorder characterized by progressive proximal muscle weakness, myotonia, myalgia, calf hypertrophy, and multiorgan involvement with cataract, cardiac conduction defects, and endocrine disorders (<xref ref-type="bibr" rid="bib42">Meola and Cardani, 2015</xref>; <xref ref-type="bibr" rid="bib48">Montagnese et al., 2017</xref>). The disease is caused by a (CCTG)<sub>n</sub> repeat expansion in intron 1 of the <italic>CNBP</italic> gene (previously <italic>ZNF9</italic>; MIM*116955) on chromosome 3q21.3 (<xref ref-type="bibr" rid="bib35">Liquori et al., 2001</xref>). The CCTG repeat tract is part of a complex (TG)<sub>v</sub> (TCTG)<sub>w</sub> (CCTG)<sub>x</sub> motif that, in healthy-range alleles, is generally interrupted by one or more GCTG, TCTG, or ACTG (NCTG) motifs that confer repeat stability (<xref ref-type="bibr" rid="bib56">Radvanszky et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Mahyera et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Guo and Lam, 2016</xref>). Nonpathogenic alleles contain up to 26 CCTG repeat units, whereas premutations are composed of &lt;75 ‘pure’ CCTG blocks whose clinical significance remains unclear (<xref ref-type="bibr" rid="bib40">Mahyera et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Botta et al., 2021</xref>). In DM2 patients, the number of repeats is between ~75 and &gt;11,000 units, among the largest reported so far in repeat-expansion disorders (<xref ref-type="bibr" rid="bib17">Depienne and Mandel, 2021</xref>). The DM2 mutation shows marked somatic instability and tends to increase in length over time within the same individual, but it does not show a strong bias toward intergenerational expansion, and genetic anticipation is rarely seen in DM2 families (<xref ref-type="bibr" rid="bib35">Liquori et al., 2001</xref>; <xref ref-type="bibr" rid="bib31">Kamsteeg et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Mahyera et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Thornton, 2014</xref>; <xref ref-type="bibr" rid="bib68">Udd et al., 2003</xref>).</p><p>The few genotype–phenotype studies reported so far in DM2 patients did not reveal any significant associations between the severity of the disease, including the age at onset, and the number of CCTG repeats (<xref ref-type="bibr" rid="bib14">Day et al., 2003</xref>; <xref ref-type="bibr" rid="bib68">Udd et al., 2003</xref>). The identification of such correlations is hindered by heterogeneity across tissues, somatic instability, and the technical challenges that must be overcome to measure repeat lengths accurately in such large microsatellite expansions. This has prevented the discovery of additional <italic>in cis</italic> genetic modifiers that may ameliorate or exacerbate DM2 disease symptoms. The genetic features of the <italic>CNBP</italic> microsatellite locus, as well as its extreme length and high CG content, have frustrated attempts to size and sequence expanded alleles in DM2 patients. Even the investigators in the original gene-discovery study were unable to sequence the entire CCTG array because of its length and the high level of somatic mosaicism (<xref ref-type="bibr" rid="bib35">Liquori et al., 2001</xref>; <xref ref-type="bibr" rid="bib2">Bachinski et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Day et al., 2003</xref>).</p><p>According to international guidelines, current best practice for DM2 genetic testing relies mainly on PCR-based approaches (<xref ref-type="bibr" rid="bib5">Botta et al., 2006</xref>; <xref ref-type="bibr" rid="bib31">Kamsteeg et al., 2012</xref>). These include an initial short-range PCR (SR-PCR) to exclude a DM2 diagnosis when two normal-range alleles are detected. When only one allele is visible, (CCTG)<sub>n</sub> expansions can be identified by long-range PCR (LR-PCR) or quadruplet-repeat primed PCR (QP-PCR), leading to a ~99% detection rate (<xref ref-type="bibr" rid="bib31">Kamsteeg et al., 2012</xref>). However, neither method can define the exact length of large DM2 expansions, which requires the Southern blot analysis of digested genomic DNA and has a sensitivity of ~80% (<xref ref-type="bibr" rid="bib14">Day et al., 2003</xref>). The latter method is time consuming, requires large amounts of DNA, and is not included in the routine workflow of most diagnostic centers. Moreover, none of the methods described above can resolve the expansion to the single-nucleotide level and they have a limited ability to detect minor alleles and the degree of somatic mosaicism.</p><p>Third-generation long-read sequencing technologies provide an unprecedented opportunity to fully characterize DM2 expansions in terms of repeat size, allele configuration, and base composition. Whereas most second-generation sequencing methods produce short reads, third-generation methods such as Oxford Nanopore Technologies (ONT) and PacBio SMRT sequencing facilitate the analysis of DNA fragments multiple kilobases in length, including large repetitive elements and their flanking regions. Furthermore, third-generation methods are generally based on PCR-free workflows, thus avoiding amplification-related biases (<xref ref-type="bibr" rid="bib28">Hommelsheim et al., 2014</xref>) and challenges caused by regions with a high CG content (such as the <italic>CNBP</italic> locus). However, these technologies are more expensive and error-prone than first- and second-generation methods. Targeted approaches that maximize data production on a selected region of interest can compensate for such errors and provide cost-effective alternatives to whole-genome sequencing.</p><p>Targeted enrichment approaches coupled to long-read sequencing have already been used for the in-depth characterization of repeat expansions in fragile X syndrome (<italic>FMR1</italic>), Huntington’s disease (<italic>HTT</italic>), and neuronal intranuclear inclusion disease (<italic>NOTCH2NLC</italic>), although these expansions are significantly shorter than the (CCTG)<sub>n</sub> repeats in DM2 patients (<xref ref-type="bibr" rid="bib16">DeJesus-Hernandez et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Ebbert et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Giesselmann et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Grosso et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Hafford-Tear et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Höijer et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Mizuguchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Sone et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Tsai et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Wallace et al., 2021</xref>; <xref ref-type="bibr" rid="bib70">Wieben et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Mitsuhashi and Matsumoto, 2020</xref>). The longest allele thus far characterized by third-generation sequencing is a 21-kbp allele of the <italic>C9orf72</italic> gene that causes amyotrophic lateral sclerosis and frontotemporal dementia (<xref ref-type="bibr" rid="bib16">DeJesus-Hernandez et al., 2021</xref>). In addition, many of the works cited above combined PacBio SMRT sequencing with LR-PCR (<xref ref-type="bibr" rid="bib41">Mangin et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Ciosi et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Cumming et al., 2018</xref>), which is unsuitable for the analysis of DM2 expansions due to their extreme length and high GC content. Importantly, PacBio reads do not exceed 20 kbp in a PCR-free enrichment (<xref ref-type="bibr" rid="bib16">DeJesus-Hernandez et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Ebbert et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Hafford-Tear et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Höijer et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Tsai et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">Wieben et al., 2019</xref>), and would not completely span DM2 pathogenic expansions (20 kbp on average, but up to 50 kbp).</p><p>To address these issues, we assessed the analysis of <italic>CNBP</italic> expansions using a combination of CRISPR/Cas9-based enrichment (Cas9-enrichment) and ONT sequencing. The latter can generate reads &gt;100 kbp in length (<xref ref-type="bibr" rid="bib53">Payne et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Iyer et al., 2022</xref>) and recently demonstrated valuable for the analysis of very long repetitive elements, like telomeric and centromeric regions in the completion of human genome (<xref ref-type="bibr" rid="bib61">Sergey et al., 2022</xref>; <xref ref-type="bibr" rid="bib11">Consortium and The Telomere-to-telomere T T, 2022</xref>) and microsatellite expansions in the pathogenic range (<xref ref-type="bibr" rid="bib64">Stevanovski et al., 2022</xref>). In this manner, we sequenced full-length (CCTG)<sub>n</sub> expansions in nine DM2 patients including one mutated allele 47 kbp in length. Because this approach achieves single-nucleotide resolution, we were able to detect a previously unreported (TCTG)<sub>n</sub> motif at the 3′ end of the <italic>CNBP</italic> expansion in seven of the DM2 patients. Our pilot study demonstrated that Cas9-mediated enrichment and long-read sequencing improves the DM2 diagnostic workflow, facilitating the in-depth characterization of <italic>CNBP</italic> expansions by accurately reporting the repeat length, structure/motif, and degree of somatic mosaicism in a single analysis. In the future, this approach may enable more precise genotype–phenotype correlations and thus improve patient stratifications in clinical trials for personalized therapies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Molecular characterization of DM2 patients using traditional methods</title><p>We analyzed nine DM2 patients (six males and three females, mean age = 46.4 ± 20 years) with existing molecular diagnoses based on a combination of PCR-based approaches (SR-PCR, LR-PCR, and QP-PCR) to detect the presence of (CCTG)<sub>n</sub> expansions in the <italic>CNBP</italic> gene (<xref ref-type="table" rid="table1">Table 1</xref>). Four patients were familial cases (A1–A4) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) whereas patients B, C, D, E, and F were sporadic cases. The maximum length of the (CCTG)<sub>n</sub> expansion could not be determined using routine diagnostic methods, so we digested genomic DNA and estimated the size of each allele by Southern blot analysis (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). This suggested that the size of the microsatellite ranged from 20 to about 40 kbp (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). As expected, no signal was detected for healthy control subjects (CTR) or myotonic dystrophy type 1 (DM1) patient (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The characterization of normal <italic>CNBP</italic> alleles by SR-PCR and Sanger sequencing revealed the presence of eight short interrupted alleles with the structure (TG)<sub>17–24</sub> (TCTG)<sub>6–9</sub> (CCTG)<sub>5–7</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub> and one short uninterrupted allele with the structure (TG)<sub>19</sub> (TCTG)<sub>9</sub> (CCTG)<sub>12</sub>, matching our previous results for an Italian population (<xref ref-type="bibr" rid="bib7">Botta et al., 2021</xref>; <xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Demographic and molecular features of the dystrophy type 2 (DM2) patients.</title><p>For each patient, the table shows the ID, sex, age, age at onset, repeat length, and structure of the <italic>CNBP</italic> normal allele characterized by Sanger sequencing, and the estimated repeat length of the expanded allele determined by Southern blotting (–, not available).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="4"/><th align="left" valign="bottom" colspan="2">Normal allele</th><th align="left" valign="bottom">Expanded allele</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Sample ID</bold></td><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"><bold>Age</bold></td><td align="left" valign="bottom"><bold>Age at onset</bold></td><td align="left" valign="bottom"><bold>Repeat length (bp</bold>)</td><td align="left" valign="bottom"><bold>Repeat structure</bold></td><td align="left" valign="bottom"><bold>Repeat length (bp</bold>)</td></tr><tr><td align="left" valign="bottom">A1</td><td align="left" valign="bottom">F</td><td align="char" char="." valign="bottom">75</td><td align="char" char="." valign="bottom">70</td><td align="char" char="." valign="bottom">136</td><td align="left" valign="bottom">(TG)<sub>24</sub> (TCTG)<sub>7</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">40,000</td></tr><tr><td align="left" valign="bottom">A2</td><td align="left" valign="bottom">M</td><td align="char" char="." valign="bottom">27</td><td align="char" char="." valign="bottom">25</td><td align="char" char="." valign="bottom">130</td><td align="left" valign="bottom">(TG)<sub>17</sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">20,000</td></tr><tr><td align="left" valign="bottom">A3</td><td align="left" valign="bottom">M</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">–</td><td align="char" char="." valign="bottom">132</td><td align="left" valign="bottom">(TG)<sub>20</sub> (TCTG)<sub>8</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">20,323</td></tr><tr><td align="left" valign="bottom">A4</td><td align="left" valign="bottom">M</td><td align="char" char="." valign="bottom">65</td><td align="char" char="." valign="bottom">61</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">(TG)<sub>19</sub> (TCTG)<sub>9</sub> (CCTG)<sub>12</sub></td><td align="char" char="." valign="bottom">32,745</td></tr><tr><td align="left" valign="bottom">B</td><td align="left" valign="bottom">F</td><td align="char" char="." valign="bottom">49</td><td align="char" char="." valign="bottom">44</td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom">(TG)<sub>21</sub> (TCTG)<sub>7</sub> (CCTG)<sub>6</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">40,000</td></tr><tr><td align="left" valign="bottom">C</td><td align="left" valign="bottom">M</td><td align="char" char="." valign="bottom">20</td><td align="left" valign="bottom">–</td><td align="char" char="." valign="bottom">140</td><td align="left" valign="bottom">(TG)<sub>24</sub> (TCTG)<sub>6</sub> (CCTG)<sub>7</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">29,027</td></tr><tr><td align="left" valign="bottom">D</td><td align="left" valign="bottom">M</td><td align="char" char="." valign="bottom">44</td><td align="char" char="." valign="bottom">39</td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom">(TG)<sub>19</sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">20,000</td></tr><tr><td align="left" valign="bottom">E</td><td align="left" valign="bottom">F</td><td align="char" char="." valign="bottom">61</td><td align="char" char="." valign="bottom">43</td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom">(TG)<sub>19</sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">30,000</td></tr><tr><td align="left" valign="bottom">F</td><td align="left" valign="bottom">M</td><td align="char" char="." valign="bottom">56</td><td align="char" char="." valign="bottom">50</td><td align="char" char="." valign="bottom">138</td><td align="left" valign="bottom">(TG)<sub>21</sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">39,000</td></tr></tbody></table></table-wrap><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cas9-mediated sequencing of the <italic>CNBP</italic> microsatellite.</title><p>(<bold>A</bold>) Experimental methods applied retrospectively to study the <italic>CNBP</italic> microsatellite in nine confirmed dystrophy type 2 (DM2) patients. The positions of AluI and HaeIII restriction sites (142 bp upstream and 108 bp downstream of the CCTG array, respectively) and the (CCTG)<sub>5</sub> probe (orange rectangle) for Southern blot hybridization are shown, along with the gRNAs cleavage site for Cas9-mediated enrichment (boundaries of blue line = 4.2 kb) and the annealing position of P4TCTG primers for quadruplet-repeat primed PCR (QP-PCR). (<bold>B</bold>) Average coverage and (<bold>C</bold>) fold enrichment obtained by Cas9-mediated enrichment in DM2 patients following singleplex (<italic>n</italic> = 4) or multiplex (<italic>n</italic> = 4) runs. Numbers above bars represent the percentage of on-target reads. (<bold>D</bold>) Total and on-target number of PASS reads generated for each DM2 patient and (<bold>E</bold>) number of reads fully spanning the <italic>CNBP</italic> microsatellite and attributable to either the normal or expanded alleles. Data are plotted as means ± standard error of the mean (SEM). WG, whole genome. Sequencing statistics of singleplex and multiplex experiments are reported in detail in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Pedigree of the dystrophy type 2 (DM2) family analyzed.</title><p>Genetic pedigree showing the relationship among A1–A4 familiar cases analyzed in this study. DNA sample from III-5 was not available for ONT sequencing.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Southern blot analysis of expanded alleles in dystrophy type 2 (DM2) patients.</title><p>(<bold>A</bold>) Restriction map of the <italic>DM2</italic> locus indicating the AluI and HaeIII restriction sites used for the digestion of genomic DNA. (<bold>B</bold>) Southern blot analysis of genomic DNA double digested with AluI and HaeIII and probed with a digoxigenin (DIG)-labeled (CCTG)<sub>5</sub> locked nucleic acid (LNA) probe. Lane 1, CTR, healthy control sample; lane 2, DM1 sample; lanes 3–11, DM2 samples. Molecular markers are indicated on the left. The original scan of the Southern blot analysis reported in panel B and the whole figure incorporating the original uncropped scan can be found in <xref ref-type="supplementary-material" rid="fig1s2sdata1 fig1s2sdata2">Figure 1—figure supplement 2—source data 1 and 2</xref>, respectively.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Original scan of the Southern blot analysis reported in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80229-fig1-figsupp2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title><xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> including the original uncropped scan of the Southern blot analysis.</title><p>(A) Restriction map of the dystrophy type 2 (DM2) locus indicating the AluI and HaeIII restriction sites used for the digestion of genomic DNA. (B) Southern blot analysis of genomic DNA double digested with AluI and HaeIII and probed with a digoxigenin (DIG)-labeled (CCTG)<sub>5</sub> locked nucleic acid (LNA) probe. Lane 1, CTR, healthy control sample; lane 2, DM1 sample; lanes 3–11, DM2 samples. Molecular markers are indicated on the left. *indicates aspecific bands, as reported by <xref ref-type="bibr" rid="bib50">Nakamori et al., 2009</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80229-fig1-figsupp2-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig1-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>CNBP</italic> repeat-expansion analysis by Cas9-mediated enrichment coupled to ONT sequencing</title><p>We characterized the full-length <italic>CNBP</italic> expansions at single-nucleotide resolution by ONT sequencing following Cas9-mediated enrichment. Accordingly, we designed two gRNAs to excise a 4.2-kbp fragment spanning the <italic>CNBP</italic> repeat on chromosome 3q21.3 (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>Genomic DNA from the nine DM2 patients was analyzed in four singleplex and four multiplex runs, the latter applied to clinical samples here for the first time (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Cas9-mediated sequencing achieved good target coverage in all experiments, with 346 ± 64 reads (mean ± standard error of the mean) on the <italic>CNBP</italic> locus (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Singleplex runs had consistently lower background than multiplex runs (0.08× vs. 0.57×), and thus achieved a higher average fold enrichment (3521- vs. 637-fold) (<xref ref-type="fig" rid="fig1">Figure 1B, C</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Collectively, for each DM2 patient, we generated a mean total of 105,737 PASS reads, 308 of which were on target (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) and 186 of which completely spanned the normal or expanded alleles (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Only these ‘complete sequences’ were used for subsequent analysis, representing ~78% and~22% of the normal and expanded repeat-spanning reads, respectively (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>The de novo assembly of reads derived from the normal <italic>CNBP</italic> alleles in DM2 patients (145 on average per sample, IQR = 67; <xref ref-type="fig" rid="fig1">Figure 1E</xref>) showed that the complex (TG)<sub>v</sub> (TCTG)<sub>w</sub> (CCTG)<sub>x</sub> (NCTG)<sub>y</sub> (CCTG)<sub>z</sub> repeat ranged in size from 122 to 141 bp, corresponding to 12–15 CCTG quadruplets (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig2">Figure 2B</xref>). The size and repeat pattern in each patient were largely consistent with the Sanger sequencing data (99.5% mean accuracy, Pearson’s <italic>r</italic>=0.971, p &lt; 0.0001; <xref ref-type="fig" rid="fig2">Figure 2C</xref>), with six patients showing a perfect match, two differing at a single-nucleotide position and only one differing at two nucleotide positions (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title><italic>CNBP</italic> repeat analysis based on Cas9-mediated sequencing of the normal alleles.</title><p>For each patient, the table shows the characteristics of normal <italic>CNBP</italic> alleles based on the analysis of ONT sequencing data, in terms of length and structure. The table reports the percentage identity of consensus sequences reconstructed from ONT or Sanger sequencing data and the incongruences in ONT-derived sequences are highlighted in bold.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Normal allele</th><th align="left" valign="bottom">Sample ID</th><th align="left" valign="bottom">Repeat length (bp)</th><th align="left" valign="bottom">Repeat structure</th><th align="left" valign="bottom">Identity with Sanger sequence</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A1</td><td align="char" char="." valign="bottom">136</td><td align="left" valign="bottom">(TG)<sub>24</sub> (TCTG)<sub>7</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">100.0%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A2</td><td align="char" char="." valign="bottom">131</td><td align="left" valign="bottom">(TG)<sub>17</sub> T<bold>G</bold>CTG (TCTG)<sub>8</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">99.2%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A3</td><td align="char" char="." valign="bottom">132</td><td align="left" valign="bottom">(TG)<sub>20</sub> (TCTG)<sub>8</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">100.0%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A4</td><td align="char" char="." valign="bottom">122</td><td align="char" char="." valign="bottom">(TG)<sub>19</sub> (TCTG)<sub>9</sub> (CCTG)<sub>12</sub></td><td align="char" char="." valign="bottom">100.0%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">B</td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom">(TG)<sub>21</sub> (TCTG)<sub>7</sub> (CCTG)<sub>6</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">100.0%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">141</td><td align="left" valign="bottom">(TG)<sub>24</sub> T<bold>G</bold>CTG (TCTG)<sub>5</sub> (CCTG)<sub>7</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">99.3%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">D</td><td align="char" char="." valign="bottom">138</td><td align="left" valign="bottom">(<bold>TG</bold>)<sub><bold>21</bold></sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">97.1%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">E</td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom">(TG)<sub>19</sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">100.0%</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">F</td><td align="char" char="." valign="bottom">138</td><td align="left" valign="bottom">(TG)<sub>21</sub> (TCTG)<sub>9</sub> (CCTG)<sub>5</sub> GCTG CCTG TCTG (CCTG)<sub>7</sub></td><td align="char" char="." valign="bottom">100.0%</td></tr></tbody></table></table-wrap><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Analysis of ONT sequencing data from normal and expanded <italic>CNBP</italic> alleles.</title><p>(<bold>A</bold>) Integrative Genomics Viewer (IGV) visualization of ONT sequencing data at the <italic>CNBP</italic> locus of a representative dystrophy type 2 (DM2) patient following Cas9-mediated enrichment. Reads generated from the normal allele feature clear cuts on both sides of the <italic>CNBP</italic> repeat, whereas those derived from the expanded allele are longer, soft-clipped and do not match the reference genome, as expected. Length distributions of reads derived from the normal alleles (<bold>B</bold>) and expanded alleles (<bold>D</bold>) of each patient. Boxes represent the interquartile range (IQR) of lengths, the horizontal line is the median, whiskers and outliers are plotted according to Tukey’s method. (<bold>C</bold>) Correlation between the length of ONT and Sanger consensus sequences for the normal allele (<italic>n</italic> = 9). (<bold>E</bold>) Correlations between the maximum length of ONT sequences (longest complete read) and the upper edge of the Southern blot trace for the expanded allele (<italic>n</italic> = 9). Numbers on top of panels (<bold>B</bold>) and (<bold>D</bold>) indicate the coefficient of variation of normal and expanded alleles, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig2-v2.tif"/></fig><p>Reads derived from the expanded alleles (41 on average per sample, IQR = 11; <xref ref-type="fig" rid="fig1">Figure 1E</xref>) ranged from 344 bp to as much as 46.6 kbp (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), confirming the presence of extremely large expansions in these patients. To our knowledge, the latter is the longest repeat expansion analyzed thus far at single-nucleotide resolution (<xref ref-type="bibr" rid="bib45">Mizuguchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Sone et al., 2019</xref>; <xref ref-type="bibr" rid="bib21">Giesselmann et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Wallace et al., 2021</xref>) and is one of the longest DNA fragments captured by Cas9-mediated enrichment with no specific adjustment (<xref ref-type="bibr" rid="bib22">Gilpatrick et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Iyer et al., 2020</xref>). Considering average values per sample, the number of repetitive quadruplets varied from 1371 to 4421, corresponding to expansion lengths of 5485–17,685 bp. Moreover, in each patient, the longest molecule sequenced with ONT (derived from the expanded allele) largely agreed with the Southern blot estimates (Pearson’s <italic>r</italic> = 0.6840, p = 0.0422, <xref ref-type="fig" rid="fig2">Figure 2E</xref>), with the exception of sample (B). Even within the same individual, the mean size of reads derived from the expanded allele was consistently more variable than that from the normal allele (65% ± 0.091 vs. 4% ± 0.002; <xref ref-type="fig" rid="fig2">Figure 2B–D</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>). Such pronounced variability within each DM2 patient indicates extensive mosaicism, in agreement with previous reports (<xref ref-type="bibr" rid="bib35">Liquori et al., 2001</xref>; <xref ref-type="bibr" rid="bib2">Bachinski et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Day et al., 2003</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Analysis of the expanded-repeat <italic>CNBP</italic> alleles in dystrophy type 2 (DM2) patients.</title><p>Integrative Genomics Viewer (IGV) visualization (35-kbp windows) of ONT-targeted sequencing data from the expanded alleles of four representative DM2 patients. Complete reads were aligned at the 5′ end (<bold>A</bold>) and then at the 3′ end (<bold>B</bold>) in order to identify the repeat pattern that characterizes the expanded microsatellite locus. Each motif in the expanded alleles was visualized using a different color, as indicated in the key. Samples C and E contained a ‘pure’ CCTG expansion (blue) whereas samples A4 and A2 also contained the unexpected TCTG motif (red) downstream of CCTG. (<bold>C</bold>) Abundance of quadruplets identified in each patient. The <italic>y</italic>-axis shows the number of ONT reads with a certain number of repeats, whereas the <italic>x</italic>-axis shows the number of quadruplet repeats identified. ONT reads were grouped into 500 bp bins. The gray line represents the estimated kernel density of the underlying solid gray distribution of ONT reads.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of the <italic>CNBP</italic> repeat motif for the expanded alleles in dystrophy type 2 (DM2) patients.</title><p>Integrative Genomics viewer (IGV) visualization (53-kbp window) of ONT-targeted sequencing data from the expanded alleles of the five remaining DM2 samples. Complete reads were aligned at the 5′ end (<bold>A</bold>) and subsequently at the 3′ end (<bold>B</bold>) in order to identify the repeat pattern characterizing the expanded microsatellite locus. Each motif in the expanded alleles was visualized using a different color, as indicated in the key. All samples feature the unexpected TCTG motif of variable length downstream of the CCTG motif. (<bold>C</bold>) Abundance of quadruplets identified in each patient. The <italic>y</italic>-axis shows the number of ONT reads with a certain number of repeats, whereas the <italic>x</italic>-axis shows the number of quadruplet repeats identified. ONT reads were grouped into 500 bp bins. The gray line represents the estimated kernel density of the underlying solid gray distribution of ONT reads. (<bold>D</bold>) IGV visualization of ONT-targeted sequencing data from the expanded alleles of two representative patients (E and A3) carrying a pure CCTG expansion and a repeat with the TCTG motif, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Analysis of the <italic>CNBP</italic> 5′-end (TG)<sub>v</sub> repeat motif of the CNBP expanded alleles of A1–A4 dystrophy type 2 (DM2) family members.</title><p>Integrative Genomics viewer (IGV) visualization (~130 bp window) of ONT-targeted sequencing data from the expanded alleles of the DM2 family members. Complete reads were aligned at the 5′ end in order to identify the repeat pattern characterizing the expanded microsatellite locus. Nucleotides of the expanded repeat have been colored with A: green, C: blue, G: orange, and T: red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig3-figsupp2-v2.tif"/></fig></fig-group><p>To characterize the repeat pattern across the expanded microsatellite locus, we identified the quadruplet motifs in each individual read, and highlighted them with distinct colors after aligning ‘complete sequences’ at the 5′ and 3′ ends (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>). The total number of quadruplets was highly variable within each patient, thus confirming the extensive donor-dependent mosaicism described above (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). For example, reads from patient C carried on average 3000 quadruplets (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), but the number of (CCTG) repeats in individual reads varied from 150 up to 8000 (<xref ref-type="table" rid="table3">Table 3</xref>). Since we analyzed only those reads containing at least 600 bp up-/downstream the <italic>CNBP</italic> microsatellite, and thus comprising the repeat entirely, we excluded that such large variability could be ascribed to the analysis of fragmented DNA molecules.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title><italic>CNBP</italic> repeat analysis based on Cas9-mediated sequencing of the expanded alleles.</title><p>For each patient, the table shows the characteristics of expanded <italic>CNBP</italic> alleles based on the analysis of ONT sequencing data, in terms of length and structure. The expanded (CCTG)<sub>x</sub> are colored in blue and (TCTG)<sub>y</sub> in red. Potential incongruences in ONT-derived sequences are highlighted in bold. The table indicates also the fraction of reads carrying the unexpected TCTG motif at the 3′ end of the <italic>CNBP</italic> microsatellite expansion.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Expanded allele</th><th align="left" valign="bottom">Sample ID</th><th align="left" valign="bottom">Repeat length (bp) (<italic>min–max</italic>)</th><th align="left" valign="bottom">Repeat structure</th><th align="left" valign="bottom">Number of reads carrying the TCTG motif</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A1</td><td align="char" char="ndash" valign="bottom">3241–46,685</td><td align="left" valign="bottom">(<bold>TG</bold>)<sub><bold>20</bold></sub> (TCTG)<sub>7</sub> (<named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">1000</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">12</named-content><named-content content-type="author-callout-style-a1">,</named-content><named-content content-type="author-callout-style-a1">000</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">10</named-content></sub></td><td align="char" char="." valign="bottom">14 (45%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A2</td><td align="char" char="ndash" valign="bottom">864–23,779</td><td align="left" valign="bottom">(TG)<sub>18</sub> (TCTG)<sub>7</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">1000</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">4500</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">2000</named-content></sub></td><td align="char" char="." valign="bottom">92 (86%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A3</td><td align="char" char="ndash" valign="bottom">4429–18,983</td><td align="left" valign="bottom">(<bold>TG</bold>)<sub><bold>19</bold></sub> (TCTG)<sub>7</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">3000</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">5000</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">25</named-content></sub></td><td align="char" char="." valign="bottom">8 (73%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">A4</td><td align="char" char="ndash" valign="bottom">660–34,284</td><td align="left" valign="bottom">(TG)<sub>18</sub> (TCTG)<sub>7</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">250</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">8000</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">1500</named-content></sub></td><td align="char" char="." valign="bottom">9 (29%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">B</td><td align="char" char="ndash" valign="bottom">344–23,358</td><td align="left" valign="bottom">(TG)<sub>18</sub> (TCTG)<sub>7</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">300</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">4000</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">400</named-content></sub></td><td align="char" char="." valign="bottom">6 (23%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">C</td><td align="char" char="ndash" valign="bottom">700–31,753</td><td align="char" char="." valign="bottom">(TG)<sub>20</sub> (TCTG)<sub>7</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">150</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">8000</named-content></sub></td><td align="char" char="." valign="bottom">0 (0%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">D</td><td align="char" char="ndash" valign="bottom">383–19,143</td><td align="left" valign="bottom">(TG)<sub>18</sub> (TCTG)<sub>7</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">100</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">4000</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">1000</named-content></sub></td><td align="char" char="." valign="bottom">3 (11%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">E</td><td align="char" char="ndash" valign="bottom">848–25,162</td><td align="char" char="." valign="bottom">(TG)<sub>18</sub> (TCTG)<sub>6</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">200</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">6200</named-content></sub></td><td align="char" char="." valign="bottom">0 (0%)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">1533–32,824</td><td align="left" valign="bottom">(TG)<sub>15</sub> (TCTG)<sub>10</sub> <named-content content-type="author-callout-style-a1">(</named-content><named-content content-type="author-callout-style-a1">CCTG</named-content><named-content content-type="author-callout-style-a1">)</named-content><sub><named-content content-type="author-callout-style-a1">400</named-content><named-content content-type="author-callout-style-a1">–</named-content><named-content content-type="author-callout-style-a1">6000</named-content></sub> <named-content content-type="author-callout-style-a3">(</named-content><named-content content-type="author-callout-style-a3">TCTG</named-content><named-content content-type="author-callout-style-a3">)</named-content><sub><named-content content-type="author-callout-style-a3">0</named-content><named-content content-type="author-callout-style-a3">–</named-content><named-content content-type="author-callout-style-a3">2000</named-content></sub></td><td align="char" char="." valign="bottom">15 (43%)</td></tr></tbody></table></table-wrap><p>A variable number of (TG)<sub>v</sub> repetitions upstream of the (CCTG)<sub>n</sub> array was also observed in the familiar cases A1–A4 (<xref ref-type="table" rid="table3">Table 3</xref>). Since this microsatellite tract is supposed to be stably transmitted within the same family, the observed discrepancy was likely an artefact due to ONT accuracy, as reported for the healthy alleles. Manual inspection of sequencing data indeed confirmed that all family members show an equivalent pattern of (TG)<sub>v</sub> repetitions (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><p>The uninterrupted (TG)<sub>v</sub> (TCTG)<sub>w</sub> (CCTG)<sub>x</sub> motif that characterizes expanded <italic>CNBP</italic> alleles was found at the 5′ end of the repeat locus in all nine patients (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, and <xref ref-type="table" rid="table3">Table 3</xref>). However, only two patients featured a ‘pure’ pattern of (CCTG)<sub>n</sub> repeats. In the remaining seven, we observed additional (TCTG)<sub>n</sub> arrays (colored in red) at the 3′ end of the CCTG expansion, which has been never reported in DM2 patients before (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, and <xref ref-type="table" rid="table3">Table 3</xref>). When present, the TCTG motif was detected in a highly variable fraction of sequences (11%–86% of the expanded allele reads, <xref ref-type="table" rid="table3">Table 3</xref>), and differed widely in length (40–8000 bp) between donors and within the same individual (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, and <xref ref-type="table" rid="table3">Table 3</xref>).</p></sec><sec id="s2-3"><title>Analysis of the TCTG repeat using orthogonal methods</title><p>To confirm the presence of the (TCTG)<sub>n</sub> motifs in the <italic>CNBP</italic> expanded alleles, we used a traditional QP-PCR method for the selective amplification of TCTG blocks at the 3′ end of the (CCTG)<sub>n</sub> array (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In agreement with the ONT data, QP-PCR analysis using primer P4TCTG revealed an electrophoretic profile compatible with the presence of (TCTG)<sub>n</sub> downstream of the (CCTG)<sub>n</sub> expansion in seven DM2 samples (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The intensity and pattern of fluorescent peaks obtained using primer P4TCTG were more variable across samples compared to the routine protocol using the standard P4CCTG primer, possibly due to different levels of somatic mosaicism in the TCTG and CCTG expansions. A 260 bp signal was visible in all samples, including the DM2 negative controls (one DM1 positive patient and one healthy subject CTR), suggesting it was a PCR artifact (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Interestingly, the two patients with ‘pure’ (CCTG)<sub>n</sub> expansions based on ONT data (patients C and E) did not yield amplification peaks within the expansion range with the P4TCTG primer (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Fluorescent signals &lt;140 bp were visible in these samples because normal <italic>CNBP</italic> alleles also contain (TCTG)<sub>n</sub> repeats at their 5′ end (<xref ref-type="table" rid="table1">Table 1</xref>). The direct sequencing of QP-PCR products generated using primer P4TCTG confirmed the presence of (TCTG)<sub>n</sub> motif in DM2 patients A1, A2, A3, A4, B, D, and F, thus supporting the ONT data (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Analysis of the TCTG motif by quadruplet-repeat primed PCR (QP-PCR) and Sanger sequencing.</title><p>(<bold>A</bold>) Representative QP-PCR profiles of genomic DNA samples from patients A2 and A4 and showing the presence of the TCTG block. Upper panels show QP-PCR results using the conventional P4CCTG primer. Lower panels show QP-PCR results using primer P4TCTG. (<bold>B</bold>) Sanger sequencing of the QP-PCR products from P4TCTG reaction confirming the presence of the TCTG sequence. (<bold>C</bold>) QP-PCR profiles of genomic DNA samples from patients C and E showing only the traditional dystrophy type 2 (DM2) motif CCTG. For each patient, the composition of <italic>CNBP</italic> expanded alleles above the QP-PCR tracks reflects the ONT sequencing data. Asterisks (*) indicate nonspecific signals, also visible in the QP-PCR profiles of DM1 and CTR samples (<bold>D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Sanger sequencing of quadruplet-repeat primed PCR (QP-PCR) products showing the presence of the (TCTG)<sub>n</sub> motif.</title><p>QP-PCR was carried out using primer P4TCTG and genomic DNA from dystrophy type 2 (DM2) patients A1, A3, B, D, and F. Sanger sequencing of the QP-PCR products confirmed the presence of the (TCTG)<sub>n</sub> array at the 3′ end of the (CCTG) expansions.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80229-fig4-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The analysis of extremely long microsatellite expansions is challenging, preventing the in-depth characterization of <italic>CNBP</italic> mutations underlying DM2 and its relationship with the clinical phenotype. To date, the genotype–phenotype correlation issue in DM2 is still unsolved and relies on a single study from <xref ref-type="bibr" rid="bib14">Day et al., 2003</xref> in which Southern blot analysis was used to determine the length of DM2 mutation. Because of the extremely large size of the CCTG expansions and somatic instability of the repeat, Southern blot fails to detect the DM2 mutation in about 20% of known carriers, whose expansion length remains undeterminable. Moreover, currently no diagnostic method allows to sequence through fully expanded <italic>CNBP</italic> microsatellites. Here, we have demonstrated for the first time the use of Cas9-mediated enrichment and ONT long-read sequencing to analyze the full (CCTG)<sub>n</sub> expansion in DM2 patients at single-nucleotide resolution. We were able to characterize normal and expanded <italic>CNBP</italic> alleles, simultaneously revealing the repeat length, structure/motif, and extent of somatic mosaicism, which is not possible with traditional methods, even if several are used in combination.</p><p>The paucity of genotype–phenotype data for DM2 reflects the historical inability to determine the size of CCTG repeats, especially in the largest expansions, which traditionally was based on the Southern blot analysis of genomic DNA. This labor-intensive and time-consuming technique is becoming obsolete because it requires large amounts of high-molecular-weight DNA. LR-PCR can be used instead, but the performance of this technique is poor in regions with a high CG content, and it cannot accommodate the very large expanded alleles (&gt;15 kbp) often found in DM2. Therefore, although LR-PCR achieves the sensitive detection of DM2 mutations, the full length of the (CCTG)<sub>n</sub> expansion cannot be determined in all patients. Our Cas9-targeted sequencing protocol overcomes these limits by focusing long-read sequencing data on the <italic>CNBP</italic> microsatellite, with reads spanning the entire expansion. The length of normal and expanded alleles in DM2 patients determined using this new approach closely matched the values obtained with the traditional reference methods. The mean size of normal <italic>CNBP</italic> alleles was 134 bp whereas expanded alleles ranged from 344 to 46,685 bp, in agreement with previous reports (<xref ref-type="bibr" rid="bib42">Meola and Cardani, 2015</xref>; <xref ref-type="bibr" rid="bib48">Montagnese et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Botta et al., 2021</xref>). A single incongruence was observed for one expanded allele in patient B, where ONT sequencing underestimated the size determined by Southern blotting (~20 vs. ~40 kbp). A possible explanation is the presence of damaged DNA in the sample, reflecting its long-term storage in a biobank. Southern blotting involves the fractionation of double-stranded DNA, which would be unaffected by the presence of nicked strands, whereas ONT sequencing involves the analysis of single DNA strands, so the presence of nicks would have a profound effect (<xref ref-type="bibr" rid="bib51">Oxford Nanopore Community, 2021</xref>). Even so, Cas9-mediated enrichment allowed us to sequence DM2 alleles up to ~50 kbp in length at single-nucleotide resolution, which has not been reported previously for DM2 or any other repeat-expansion disorder using this approach (<xref ref-type="bibr" rid="bib21">Giesselmann et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Mizuguchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Sone et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Wallace et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Gilpatrick et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Iyer et al., 2020</xref>). The analysis of such long and repetitive alleles required the coupling of a PCR-free enrichment protocol to ONT sequencing because even other long-read sequencing technologies cannot accommodate this read length in targeted sequencing experiments. For example, PacBio long-read sequencing was previously used to sequence repeat expansions in DM1, which is also characterized by long alleles of 4–6 kbp, but the microsatellites were first amplified by PCR (<xref ref-type="bibr" rid="bib41">Mangin et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Cumming et al., 2018</xref>). Even when coupled to PCR-free enrichment approach based on Cas9, the length of PacBio sequencing reads could not exceed 20 kbp (<xref ref-type="bibr" rid="bib16">DeJesus-Hernandez et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Ebbert et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Hafford-Tear et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Höijer et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Tsai et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">Wieben et al., 2019</xref>).</p><p>Although ONT sequencing had been already utilized for the analysis of the microsatellite within the CNBP gene, this was confined to CNBP alleles in the normal range only (<xref ref-type="bibr" rid="bib64">Stevanovski et al., 2022</xref>; <xref ref-type="bibr" rid="bib46">Mohammad et al., 2022</xref>). Moreover, the work of Mitsuhashi et al. exploited ONT whole-genome sequencing, that is not applicable in the routine due to the very high costs (<xref ref-type="bibr" rid="bib46">Mohammad et al., 2022</xref>). The group of Stevanovski utilized the recently introduced ‘Read Until’ feature of ONT sequencing for the analysis of microsatellites in 37 disease-associated loci. This allows the selective sequencing of predefined genomic regions, thus enabling a targeted sequencing with similar advantages of the Cas9-mediated sequencing presented hereby. However, enrichment levels achieved by ‘Read Until’ (5×) are consistently lower than those obtained with the Cas9 approach (500×), due to higher background (<xref ref-type="bibr" rid="bib64">Stevanovski et al., 2022</xref>). This may constitute an important issue when dealing with extremely long CNBP alleles that can be disadvantaged in sequencing as compared to shorter contaminating fragments (<xref ref-type="bibr" rid="bib27">Holgersen et al., 2021</xref>).</p><p>From a technical perspective, we achieved &gt;500× enrichment on <italic>CNBP</italic> using the Cas9 protocol, which is robust and comparable to similar assays for the assessment of microsatellite length (<xref ref-type="bibr" rid="bib21">Giesselmann et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Mizuguchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Sone et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Wallace et al., 2021</xref>). We also compared Cas9-mediated singleplex versus multiplex enrichment protocols for the first time on clinical samples and observed a consistently lower performance (10-fold lower enrichment, with 70% unclassified reads) in the multiplex environment, as reported by other ONT users for other type of samples (<xref ref-type="bibr" rid="bib52">Oxford Nanopore Community, 2022</xref>). Further improvements are therefore required before the multiplexing protocol is suitable, for example by combining the Cas9 protocol with a second enrichment step using the ‘Read Until’ feature of ONT sequencing to exclude the background noise. Alternatively, costs could be optimized by analyzing single samples using Flongles, which produce less sequencing data than regular ONT flow cells but reduce costs by 90%.</p><p>The bioinformatic pipeline we used to analyze the <italic>CNBP</italic> microsatellite sequences also allowed us to recognize the repeat pattern and precisely count the repeats, including the short interrupted and uninterrupted alleles typifying the Italian population (<xref ref-type="bibr" rid="bib7">Botta et al., 2021</xref>). Consensus sequences generated from the normal allele shared a high degree of identity (99.5%) and significant correlation with state-of-the-art Sanger sequences, aside from a few nucleotide positions. Similar small discrepancies have also been reported in characterization of the (TG)<sub>v</sub> motif upstream of the (CCTG)<sub>n</sub> repeated array in familial cases A1–A4. These inconsistences probably reflect ONT sequencing errors and could be addressed by using the most recent base-calling algorithm and eventually the more accurate Q20+ chemistry.</p><p>In the expanded alleles of seven DM2 patients, the anticipated (CCTG)<sub>n</sub> repeat was accompanied by a previously unreported (TCTG)<sub>n</sub> repeat located at the 3′ end of the (CCTG)<sub>n</sub> array. When present, the atypical motif varied in length between donors and within each sample (40–8000 bp). Repeat interruptions within the expanded array have been reported in 3%–8% of DM1 patients (<xref ref-type="bibr" rid="bib66">Tomé et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Braida et al., 2010</xref>; <xref ref-type="bibr" rid="bib59">Santoro et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Santoro et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Ballester-Lopez et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Pešović et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Miller et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Radvansky et al., 2011</xref>; <xref ref-type="bibr" rid="bib62">Siena et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Botta et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Santoro et al., 2015</xref>; <xref ref-type="bibr" rid="bib1">Addis et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Fontana et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Lian et al., 2016</xref>; <xref ref-type="bibr" rid="bib33">Leeflang and Arnheim, 1995</xref>; <xref ref-type="bibr" rid="bib49">Musova et al., 2009</xref>; <xref ref-type="bibr" rid="bib12">Cumming et al., 2018</xref>), but have not been described in DM2 before. This may reflect the challenge of sequencing complete <italic>CNBP</italic> expanded alleles and/or the use of a primer containing ‘pure’ (CCTG)<sub>n</sub> repeats for diagnostic QP-PCR. Given that (TCTG)<sub>n</sub> repeats were present in a highly variable proportion of expanded alleles (11%–86%), always in the presence of the typical (CCTG)<sub>n</sub> repeats, technical bias may have revealed only the ‘pure’ (CCTG)<sub>n</sub> repeats. Indeed, a modified QP-PCR protocol using a primer containing five TCTG units – (TCTG)<sub>5</sub>T – was able to confirm the ONT sequencing data. From a biological perspective, the (TCTG)<sub>n</sub> motif may have arisen through DNA duplication/repair errors or spontaneous DNA damage in the somatic cells of DM2 patients. Although the presence of this motif may be biologically relevant in the context of DM2, our data must be interpreted with caution. First, the motif was discovered in a small set of patients, most belonging to the same family, so confirmation requires a larger prospective DM2 cohort enrolled in multicenter studies, in which DNA samples are collected in order to ensure the optimal quality for ONT sequencing. Second, considering the known limitations of ONT sequencing when presented with low-complexity regions such as homopolymers, the length and recurrence of such motifs should be investigated using other long-read methods when they are sufficiently advanced to sequence the expanded alleles completely.</p><p>The Cas9-targeted sequencing approach also allowed us to estimate the degree of somatic mosaicism for the mutated alleles, either ‘pure’ or ‘interrupted’. On average, the allele length within each patient varied by 65%. Mosaicism plays an important role in the development of disease symptoms, so establishing the relative proportion of expanded alleles in the lower and upper mutation range could add prognostic value, significantly improving genetic counseling for DM2. Extreme mosaicism (more than expected based on previous studies) has also been detected when long-read sequencing is applied to other repeat-expansion disorders, suggesting that such techniques achieve higher resolution (<xref ref-type="bibr" rid="bib36">Loomis et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Mizuguchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Mangin et al., 2021</xref>). As already demonstrated for DM1 (<xref ref-type="bibr" rid="bib13">Cumming et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Monckton et al., 1995</xref>), the progenitor allele length (i.e., the length of the CCTG repeat transmitted by the affected parent) is one genetic determinant that influences the age at onset of DM2 symptoms, and that age is further modified by individual-specific differences in the level of somatic instability. Notably, our method accurately distinguished between the shortest expanded allele and the normal allele.</p><p>Another advantage of the approach demonstrated hereby is that PCR-free analysis potentially allows the direct assessment of DNA methylation, as already reported for other repeat-linked diseases (<xref ref-type="bibr" rid="bib20">Fukuda et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Giesselmann et al., 2019</xref>). This can provide additional information concerning the impact of expansions on the functionality of the <italic>CNBP</italic> gene. The methylation of the <italic>CNBP</italic> gene has been analyzed using a pyrosequencing method, revealing hypomethylation of CpG sites upstream and hypermethylation of CpG sites downstream of the (CCTG)<sub>n</sub> expansion in DM2 patients and healthy individuals, with no significant differences between these groups (<xref ref-type="bibr" rid="bib60">Santoro et al., 2018</xref>). However, it remains possible that the DM2 mutation could have epigenetic effects in other regulatory regions of the <italic>CNBP</italic> gene and/or in different tissues.</p><p>Given the ability of our method to simultaneously determine the size, single-nucleotide composition and degree of somatic mosaicism of DM2 repeat expansions, ONT sequencing could be included in the DM2 diagnostic workflow to improve the information content available for genetic counseling. To date, the cost for Cas9-mediated sequencing of a single patient is relatively high and not comparable with the PCR-based approaches used in the routine of the DM2 molecular diagnostics. Nevertheless, targeted long-read sequencing might help to solve unusual large and complex (CCTG)<sub>n</sub> expansions not detectable with conventional methods and identifies noncanonical repetitive motif conformations and sequence interruptions. Taken together, this information will allow more precise correlation between the length and composition of DM2 expansion and the clinical phenotype. In a next future, further evolution of ONT chemistry and the optimization of multiplexing strategies are expected to drastically decrease the costs of the analysis, making the Cas9-mediated sequencing more easily accessible in the clinical practice.</p><p>Taken together, our pilot study has demonstrated the potential of PCR-free long-read sequencing for the genetic assessment of DM2, allowing us to investigate both the length and genetic features of normal and expanded alleles in a single round of analysis. The use of such an approach in larger cohorts will increase the accuracy of genotype–phenotype correlations and enhance the information content available for DM2 genetic counseling.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>CNBP</italic></td><td align="left" valign="bottom">Ensembl</td><td align="left" valign="bottom">HGNC:13164</td><td align="left" valign="bottom">Hg38</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Anti-coagulated peripheral blood</td><td align="left" valign="bottom">Policlinico Tor Vergata, Rome, Italy</td><td align="left" valign="bottom">Patient A1, A2, A3, A4, B, C, D, E, F</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Digoxigenin (DIG)-labeled locked nucleic acid (LNA) probe</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib50">Nakamori et al., 2009</xref></td><td align="left" valign="bottom">DIG-LNA probe</td><td align="char" char="." valign="bottom">(CCTG)<sub>5</sub></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">P4TCTG</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">agc gga taa caa ttt cac aca gga TCT GTC TGT CTG TCT GTC TGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CL3N58_DR-[FAM]</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCC TAG GGG ACA AAG TGA GA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">P3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGC GGA TAA CAA TTT CAC ACA GGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">crRNA1_CNBP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">CRISPR RNA</td><td align="left" valign="bottom">CCA CCT GAT TCA CTG CGA TA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">crRNA2_CNBP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">CRISPR RNA</td><td align="left" valign="bottom">GGC TTC TCA TTC CAC GAC CA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Native barcodes</td><td align="left" valign="bottom">Oxford Nanopore Technologies (ONT)</td><td align="left" valign="bottom">EXP-NBD104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DIG-High Prime DNA Labeling and Detection Starter Kit II</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat. No. 11585614910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Flexigene DNA Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat. No. 51206</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BigDye Terminator v3.1 Cycle Sequencing Kit</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat. No. 4337458</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nanobind CBB Big DNA HMW Kit</td><td align="left" valign="bottom">Circulomics</td><td align="left" valign="bottom">SKU 102-301-900</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoSpin Blood L Kit</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">Item number: 740954.20</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Qubit dsDNA BR Assay Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. No. Q32853</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TapeStation DNA ScreenTape &amp; Reagents</td><td align="left" valign="bottom">Agilent Technologies</td><td align="left" valign="bottom">Cat. No.<break/>5067–5365<break/>5067–5366</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GeneMapper Software 6</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat. No. 4475074</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CHOPCHOP</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Labun et al., 2019</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><underline>chopchop.cbu.uib.no/</underline></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Guppy v3.4.5</td><td align="left" valign="bottom">Computational Biology Research Center – AIST</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NanoFilt v2.7.1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">De Coster et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BBMap suite v38.87</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/bbmap/">https://sourceforge.net/projects/bbmap/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Tandem Repeat Finder v4.09</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Benson, 1999</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Minimap2 v2.17-r941</td><td align="left" valign="bottom">Li, 2018</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Integrative Genomics Viewer (IGV) v2.8.3</td><td align="left" valign="bottom">Robinson, 2011</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Scripts for the generation of consensus sequences and repeat annotations for the normal allele</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/CharONT2">https://github.com/MaestSi/CharONT2</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Script Name: CharONT2</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Scripts for the annotation of repeats and the generation of simplified reads for the expanded allele</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/MosaicViewer_CNBP">https://github.com/MaestSi/MosaicViewer_CNBP</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Script Name: MosaicViewer_CNBP v1.0.0</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MinKNOW V20.06.5</td><td align="left" valign="bottom">Oxford Nanopore Technologies</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Alt-R S.p. HiFi Cas9 Nuclease v3</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat. No. 1081060</td><td align="left" valign="bottom">Recombinant Cas9 nuclease for target excision (see M&amp;M)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Alt-R CRISPR-Cas9 tracrRNA</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat. No. 1072532</td><td align="left" valign="bottom">Structural RNA for gRNA formation (see M&amp;M)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">AMPure XP Beads</td><td align="left" valign="bottom">Beckman-Coulter</td><td align="left" valign="bottom">Product No. A63881</td><td align="left" valign="bottom">Magnetic beads for nucleic acid purification (see M&amp;M)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CutSmart buffer 10×</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat. No. B7204</td><td align="left" valign="bottom">Buffer for gDNA dephosphorylation, RNP formation, and target excision (see M&amp;M)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Blunt/TA Ligase Master Mix</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat. No.: M0367S</td><td align="left" valign="bottom">T4 DNA ligase for native barcode ligation to dA-tailed ends (see M&amp;M)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">FLO-MIN106D (R9.4.1) flow cell</td><td align="left" valign="bottom">Oxford Nanopore Technologies</td><td align="left" valign="bottom">FLO-MIN106D</td><td align="left" valign="bottom">Flowcell for ONT sequencing (see M&amp;M)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>DM2 patients</title><p>We retrospectively analyzed nine genetically confirmed DM2 Italian patients, whose enrollment in the study was approved by the institutional review board of Policlinico Tor Vergata (document no. 232/19). All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all nine participants and all samples and clinical information were anonymized immediately after collection using a unique alphanumeric identification code. Sociodemographic data for the DM2 patients are summarized in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s4-2"><title>Southern blotting</title><p>Genomic DNA was extracted from 500 µl of anticoagulated peripheral blood using a Flexigene DNA Kit (Qiagen, Hilden, Germany) and diluted to a final volume of 25 μl with double-distilled water. The quality and quantity of DNA were assessed using a Denovix spectrophotometer and by 1% agarose gel electrophoresis. <italic>CNBP</italic> expanded alleles were detected as previously described (<xref ref-type="bibr" rid="bib50">Nakamori et al., 2009</xref>), with modifications. Briefly, 2 μg of genomic DNA was digested with AluI and HaeIII and the fragments were resolved by 0.4% agarose gel electrophoresis at 40 V for 40 hr. After denaturation and neutralization, the DNA was transferred to a nylon membrane (MilliporeSigma, Burlington, MA) and fixed by UV cross-linking using a Stratalinker 2400 (Stratagene, San Diego, CA). The membrane was hybridized for 16 hr at 65°C with a digoxigenin (DIG)-labeled locked nucleic acid (LNA) probe (CCTG)<sub>5</sub> at a concentration of 10 pmol/ml. After washing at high stringency, the signal was revealed using the DIG High Prime DNA Labeling and Detection Starter Kit II (Roche, Basel, Switzerland) and visualized using an ImageQuant LAS 4000 device (GE Healthcare, Chicago, IL). Bands were sized by running two sets of molecular weight markers alongside the samples: DNA Molecular Weight Marker XV (Expand DNA Molecular Weight Marker, Roche) and λ DNA-HindIII Digest (New England Biolabs, Ipswich, MA).</p></sec><sec id="s4-3"><title>SR-PCR, QP-PCR, and Sanger sequencing</title><p>SR-PCR products were generated as reported earlier (<xref ref-type="bibr" rid="bib31">Kamsteeg et al., 2012</xref>; <xref ref-type="bibr" rid="bib5">Botta et al., 2006</xref>). QP-PCR targeting the 3′ end of the (CCTG)<sub>n</sub> repeat array was carried out as previously described (<xref ref-type="bibr" rid="bib9">Catalli et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">Musova et al., 2009</xref>), with modifications. Specifically, the repeat primer P4TCTG-agc gga taa caa ttt cac aca gga <named-content content-type="sequence">TCT GTC TGT CTG TCT GTC TGT</named-content> (lower case letters indicate the primer tail that does not complement the repeat) was combined with primers CL3N58_DR-[FAM]-GCC TAG GGG ACA AAG TGA GA and <named-content content-type="sequence">P3-AGC GGA TAA CAA TTT CAC ACA GGA</named-content> to target the most 3′ (TCTG)<sub>n</sub> interruptions. The length of the <italic>CNBP</italic> unexpanded alleles and QP-PCR products were determined by capillary electrophoresis on the 3500 Genetic Analyzer followed by analysis using GeneMapper 6 (Applied Biosystems, Waltham, MA). The SR-PCR and QP-PCR products were purified using the ExoSAP protocol, directly sequenced using the Big Dye Terminator Cycle Sequencing Kit v3.1 (Thermo Fisher Scientific, Waltham, MA) and visualized by capillary electrophoresis on the 3500 Genetic Analyzer as above.</p></sec><sec id="s4-4"><title>Cas9-mediated enrichment coupled to ONT sequencing</title><p>For DM2 patients A1–A4, B, and C, genomic DNA was extracted from 0.2 to 0.5 ml of peripheral blood using the Nanobind CBB Big DNA HMW Kit (Circulomics, Baltimore, MD), designed for HMW DNA extraction. For DM2 patients D, E, and F, the Nanobind CBB Big DNA HMW Kit failed, likely due to the presence of partially degraded DNA consequent to long-term blood storage. For DM2 patients D, E, and F genomic DNA was thus extracted from 1 to 2 ml whole blood using the NucleoSpin Blood L Kit (Macherey-Nagel, Düren, Germany), an extraction kit providing higher yield thanks to the capability of retaining both long and short DNA molecules. Regardless of the extraction method, the DNA was resuspended in Tris–EDTA buffer (pH 8.0) and the quantity was determined using a Qubit fluorometer (Thermo Fisher Scientific) and Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific). DNA integrity was assessed using a TapeStation 4150 device, Genomic DNA ScreenTape and Genomic DNA Reagents (ladder and sample buffer) all from Agilent Technologies (Santa Clara, CA).</p><p>We designed crRNAs using the online tool CHOPCHOP (<ext-link ext-link-type="uri" xlink:href="https://chopchop.cbu.uib.no/">https://chopchop.cbu.uib.no/</ext-link>) following ONT’s recommendations (<ext-link ext-link-type="uri" xlink:href="https://community.nanoporetech.com/info_sheets/targeted-amplification-free-dna-sequencing-using-crispr-cas/v/eci_s1014_v1_reve_11dec2018">https://community.nanoporetech.com/info_sheets/targeted-amplification-free-dna-sequencing-using-crispr-cas/v/eci_s1014_v1_reve_11dec2018</ext-link>), and making sure that the excised fragment was at least 3 kbp in length. Candidate crRNAs were manually checked for unique mapping by aligning them to the human genome (Hg38) using BLAST and excluding regions overlapping common single-nucleotide polymorphisms (MAF &gt;0.01, dbSNP database). The final crRNAs were prepared by Integrated DNA Technologies (Coralville, IA): 5′-CCA CCT GAT TCA CTG CGA TA-3′ with genomic coordinates Chr3:129,175,929–129,175,948, and 5′-GGC TTC TCA TTC CAC GAC CA-3′ with genomic coordinates Chr3:129,171,664–129,171,683. The reaction mixture comprised 10 µM of each crRNA, 10 µM of transactivation crRNA (tracrRNA) and 62 µM Alt-R S.p. HiFi Cas9 Nuclease v3 in 1× CutSmart Buffer for the generation of ribonucleoprotein (RNP) complexes (all components from Integrated DNA Technologies) according to the ONT protocol (version ENR_9084_v109_revD_04Dec2018).</p><p>The dephosphorylation, Cas9-mediated digestion, and dA-tailing of 1–10 µg input genomic DNA were carried out according to the ONT protocol. The genomic DNA was incubated with the RNPs for 20 min at 37°C and then 2 min at 80°C for enzyme inactivation. ONT sequencing adapters (AMX) were ligated to the cleaved and dA-tailed target ends for 10 min at room temperature before stopping the reaction by adding one volume of 10 mM Tris–EDTA (pH 8.0). Short fragments (&lt;3 kbp) and residual enzymes were removed by adding 0.3× AMPure XP beads (Beckman-Coulter, Brea, CA) and washing twice in long fragment buffer (ONT). The DNA was eluted by incubating for 10 min at room temperature in elution buffer (ONT). Cas9-multiplexing experiments were carried out as described above but EXP-NBD104 native barcodes (ONT) were ligated to the cleaved and dA-tailed target ends using Blunt/TA Ligase Master Mix (New England Biolabs). Samples were quantified and all available nanograms were pooled in a final volume of 65 µl nuclease-free water. ONT sequencing adapters (AMXII from EXP-NBD104) were ligated, followed by purification, washing, and elution as described above for the singleplex experiments. The purified library was mixed with 37.5 µl sequencing buffer (ONT) and 25.5 µl of library loading beads (ONT). The library was loaded onto a FLO-MIN106D (R9.4.1) flow cell and sequenced using MinKNOW v20.06.5 (ONT) until a plateau was reached.</p></sec><sec id="s4-5"><title>ONT sequence data analysis</title><p>Raw fast5 files were base called using Guppy v3.4.5 in high-accuracy mode, with parameters ‘-r -i $FAST5_DIR -s $BASECALLING_DIR <monospace>--flowcell</monospace> FLO-MIN106 <monospace>--kit</monospace> SQK-LSK109 --pt_scaling TRUE’ (the last parameter was recommended by ONT technical support to achieve the most appropriate scaling of reads with biased sequence composition, as expected for repeat motifs with low complexity). Reads from multiplexed runs were demultiplexed using Guppy v3.4.5 with parameters ‘-i $BASECALLING_DIR -s $DEMulTIPLEXING_DIR <monospace>--trim_barcodes</monospace> <monospace>--barcode_kits</monospace> EXP-NBD104’. Quality filtering was carried out using NanoFilt v2.7.1 (<xref ref-type="bibr" rid="bib15">De Coster et al., 2018</xref>), requiring a minimum quality score of 7. Reads spanning the full repeat were identified using a combination of the scripts msa.sh and cutprimers.sh from BBMap suite v38.87 (<ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/bbmap/">https://sourceforge.net/projects/bbmap/</ext-link>). In particular, we used in silico PCR with 100 bp primers annealing to the microsatellite flanking regions (minimum alignment identity = 80%), at least 600 bp up-/downstream, to extract only those reads containing the repeat entirely (<ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/MosaicViewer_CNBP/blob/main/Figures/CNBP_left_right_alignment.png">https://github.com/MaestSi/MosaicViewer_CNBP/blob/main/Figures/CNBP_left_right_alignment.png</ext-link>; <xref ref-type="bibr" rid="bib37">Maestri, 2020</xref>). These ‘complete sequences’ were extracted, aligned to either the normal or expanded allele based on length, and subsequent analysis was carried out using a <italic>k</italic>-means clustering method (<italic>k</italic> = 2). Reads from each allele and each sample were then processed separately. Length variability of normal and expanded alleles was determined using the coefficient of variation, measured by the ratio of the standard deviations to the average of the normal/expanded allele lengths.</p><p>An accurate consensus sequence was generated by collapsing reads from the normal allele as previously described, using the medaka ‘r941_min_high_g344’ model (<xref ref-type="bibr" rid="bib23">Grosso et al., 2021</xref>). Finally, the polished consensus sequence was screened for repeats using Tandem Repeat Finder v4.09 (<xref ref-type="bibr" rid="bib4">Benson, 1999</xref>). Scripts for the generation of consensus sequences and repeat annotations for the normal allele have been deposited online (<ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/CharONT2">https://github.com/MaestSi/CharONT2</ext-link>; <xref ref-type="bibr" rid="bib38">Maestri, 2022a</xref>).</p><p>Reads from the expanded allele were aligned to sequences flanking the repeat, screened for repeats containing the motifs ‘TG’, ‘CCTG’, and/or ‘TCTG’, and visualized in a genome browser (<xref ref-type="bibr" rid="bib23">Grosso et al., 2021</xref>). The extracted sequences and repeat summary file were then imported into R and used to generate a simplified version of the reads with a custom script. In particular, read coordinates corresponding to annotated repeats were replaced with a single-nucleotide stretch equal in length to the annotated repeat, with each motif corresponding to a different nucleotide stretch. In more detail, the flanking region was reported as unchanged to simplify the alignment of reads, ‘TG’ was replaced with ‘GG’, ‘CCTG’ with ‘CCCC’, ‘TCTG’ with ‘TTTT’, and remaining nonannotated portions were replaced with stretches of ‘N’ of the same length. Reverse complements were generated for simplified reads originally in the reverse orientation, and all simplified reads were aligned to the flanking sequence using Minimap2 v2.17-r941 and visualized in Integrative Genomics Viewer (IGV) v2.8.3. Scripts for the annotation of repeats and the generation of simplified reads for the expanded allele have been deposited online (<ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/MosaicViewer_CNBP">https://github.com/MaestSi/MosaicViewer_CNBP</ext-link>; <xref ref-type="bibr" rid="bib39">Maestri, 2022b</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is a partner of Genartis srl</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a partner of Genartis srl, Verona</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Validation</p></fn><fn fn-type="con" id="con4"><p>Validation</p></fn><fn fn-type="con" id="con5"><p>Software, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con6"><p>Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Supervision</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The study was approved by the institutional review board of Policlinico Tor Vergata (document no. 232/19). All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all nine participants and all samples and clinical information were anonymized immediately after collection using a unique alphanumeric identification code.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Sequencing statistics of singleplex and multiplex experiments.</title><p>The table reports the feature of each Cas9-mediated sequencing experiment performed and the sequencing statistics of each ONT run. Average values are also provided for singleplex and multiplex runs separately.</p></caption><media xlink:href="elife-80229-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80229-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The sequencing data generated in this study have been submitted to the NCBI BioProject database under accession number PRJNA818354 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA818354">https://www.ncbi.nlm.nih.gov/bioproject/PRJNA818354</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Alfano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA818354">PRJNA818354</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This research was funded by the Muscular Dystrophy Association (<ext-link ext-link-type="uri" xlink:href="https://www.mda.org/">https://www.mda.org/</ext-link>). We also thank the Italian DiMio onlus association of DM patients (<ext-link ext-link-type="uri" xlink:href="https://www.dimio.it/">https://www.dimio.it/</ext-link>) for funding to support research projects.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addis</surname><given-names>M</given-names></name><name><surname>Serrenti</surname><given-names>M</given-names></name><name><surname>Meloni</surname><given-names>C</given-names></name><name><surname>Cau</surname><given-names>M</given-names></name><name><surname>Melis</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Triplet-primed PCR is more sensitive than southern blotting-long PCR for the diagnosis of myotonic dystrophy type1</article-title><source>Genetic Testing and Molecular Biomarkers</source><volume>16</volume><fpage>1428</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1089/gtmb.2012.0218</pub-id><pub-id pub-id-type="pmid">23030650</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachinski</surname><given-names>LL</given-names></name><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Sansone</surname><given-names>V</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><name><surname>Thornton</surname><given-names>CA</given-names></name><name><surname>Moxley</surname><given-names>RT</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Rogers</surname><given-names>MT</given-names></name><name><surname>Jurkat-Rott</surname><given-names>K</given-names></name><name><surname>Lehmann-Horn</surname><given-names>F</given-names></name><name><surname>Wieser</surname><given-names>T</given-names></name><name><surname>Gamez</surname><given-names>J</given-names></name><name><surname>Navarro</surname><given-names>C</given-names></name><name><surname>Bottani</surname><given-names>A</given-names></name><name><surname>Kohler</surname><given-names>A</given-names></name><name><surname>Shriver</surname><given-names>MD</given-names></name><name><surname>Sallinen</surname><given-names>R</given-names></name><name><surname>Wessman</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>FA</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different european origins: A single shared haplotype indicates an ancestral founder effect</article-title><source>American Journal of Human Genetics</source><volume>73</volume><fpage>835</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1086/378566</pub-id><pub-id pub-id-type="pmid">12970845</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballester-Lopez</surname><given-names>A</given-names></name><name><surname>Koehorst</surname><given-names>E</given-names></name><name><surname>Almendrote</surname><given-names>M</given-names></name><name><surname>Martínez-Piñeiro</surname><given-names>A</given-names></name><name><surname>Lucente</surname><given-names>G</given-names></name><name><surname>Linares-Pardo</surname><given-names>I</given-names></name><name><surname>Núñez-Manchón</surname><given-names>J</given-names></name><name><surname>Guanyabens</surname><given-names>N</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name><name><surname>Lucia</surname><given-names>A</given-names></name><name><surname>Overend</surname><given-names>G</given-names></name><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><name><surname>Casadevall</surname><given-names>T</given-names></name><name><surname>Isern</surname><given-names>I</given-names></name><name><surname>Sánchez-Ojanguren</surname><given-names>J</given-names></name><name><surname>Planas</surname><given-names>A</given-names></name><name><surname>Rodríguez-Palmero</surname><given-names>A</given-names></name><name><surname>Monlleó-Neila</surname><given-names>L</given-names></name><name><surname>Pintos-Morell</surname><given-names>G</given-names></name><name><surname>Ramos-Fransi</surname><given-names>A</given-names></name><name><surname>Coll-Cantí</surname><given-names>J</given-names></name><name><surname>Nogales-Gadea</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A DM1 family with interruptions associated with atypical symptoms and late onset but not with A milder phenotype</article-title><source>Human Mutation</source><volume>41</volume><fpage>420</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1002/humu.23932</pub-id><pub-id pub-id-type="pmid">31608518</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Tandem repeats finder: A program to analyze DNA sequences</article-title><source>Nucleic Acids Research</source><volume>27</volume><fpage>573</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1093/nar/27.2.573</pub-id><pub-id pub-id-type="pmid">9862982</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Bonifazi</surname><given-names>E</given-names></name><name><surname>Vallo</surname><given-names>L</given-names></name><name><surname>Gennarelli</surname><given-names>M</given-names></name><name><surname>Garrè</surname><given-names>C</given-names></name><name><surname>Salehi</surname><given-names>L</given-names></name><name><surname>Iraci</surname><given-names>R</given-names></name><name><surname>Sansone</surname><given-names>V</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Italian guidelines for molecular analysis in myotonic dystrophies</article-title><source>Acta Myologica</source><volume>25</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">17039977</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Marcaurelio</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>L</given-names></name><name><surname>D’Apice</surname><given-names>MR</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Massa</surname><given-names>R</given-names></name><name><surname>G Monckton</surname><given-names>D</given-names></name><name><surname>Sangiuolo</surname><given-names>F</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification and characterization of 5’ CCG interruptions in complex DMPK expanded alleles</article-title><source>European Journal of Human Genetics</source><volume>25</volume><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2016.148</pub-id><pub-id pub-id-type="pmid">27876818</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Visconti</surname><given-names>VV</given-names></name><name><surname>Fontana</surname><given-names>L</given-names></name><name><surname>Bisceglia</surname><given-names>P</given-names></name><name><surname>Bengala</surname><given-names>M</given-names></name><name><surname>Massa</surname><given-names>R</given-names></name><name><surname>Bagni</surname><given-names>I</given-names></name><name><surname>Cardani</surname><given-names>R</given-names></name><name><surname>Sangiuolo</surname><given-names>F</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Antonini</surname><given-names>G</given-names></name><name><surname>Petrucci</surname><given-names>A</given-names></name><name><surname>Pegoraro</surname><given-names>E</given-names></name><name><surname>D’Apice</surname><given-names>MR</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A 14-year italian experience in DM2 genetic testing: frequency and distribution of normal and premutated CNBP alleles</article-title><source>Frontiers in Genetics</source><volume>12</volume><elocation-id>668094</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.668094</pub-id><pub-id pub-id-type="pmid">34234810</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braida</surname><given-names>C</given-names></name><name><surname>Stefanatos</surname><given-names>RKA</given-names></name><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Mahajan</surname><given-names>N</given-names></name><name><surname>Smeets</surname><given-names>HJM</given-names></name><name><surname>Niel</surname><given-names>F</given-names></name><name><surname>Goizet</surname><given-names>C</given-names></name><name><surname>Arveiler</surname><given-names>B</given-names></name><name><surname>Koenig</surname><given-names>M</given-names></name><name><surname>Lagier-Tourenne</surname><given-names>C</given-names></name><name><surname>Mandel</surname><given-names>JL</given-names></name><name><surname>Faber</surname><given-names>CG</given-names></name><name><surname>de Die-Smulders</surname><given-names>CEM</given-names></name><name><surname>Spaans</surname><given-names>F</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients</article-title><source>Human Molecular Genetics</source><volume>19</volume><fpage>1399</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq015</pub-id><pub-id pub-id-type="pmid">20080938</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catalli</surname><given-names>C</given-names></name><name><surname>Morgante</surname><given-names>A</given-names></name><name><surname>Iraci</surname><given-names>R</given-names></name><name><surname>Rinaldi</surname><given-names>F</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2)</article-title><source>The Journal of Molecular Diagnostics</source><volume>12</volume><fpage>601</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.2353/jmoldx.2010.090239</pub-id><pub-id pub-id-type="pmid">20616365</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciosi</surname><given-names>M</given-names></name><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Chatzi</surname><given-names>A</given-names></name><name><surname>Larson</surname><given-names>E</given-names></name><name><surname>Tottey</surname><given-names>W</given-names></name><name><surname>Lomeikaite</surname><given-names>V</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Wheeler</surname><given-names>VC</given-names></name><name><surname>Pinto</surname><given-names>RM</given-names></name><name><surname>Kwak</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>AJ</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Approaches to sequence the HTT CAG repeat expansion and quantify repeat length variation</article-title><source>Journal of Huntington’s Disease</source><volume>10</volume><fpage>53</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3233/JHD-200433</pub-id><pub-id pub-id-type="pmid">33579864</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Consortium</collab><collab>The Telomere-to-telomere T T</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Implications of the first complete human genome assembly</article-title><source>Genome Research</source><volume>32</volume><fpage>595</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1101/gr.276723.122</pub-id><pub-id pub-id-type="pmid">35361622</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Hamilton</surname><given-names>MJ</given-names></name><name><surname>Robb</surname><given-names>Y</given-names></name><name><surname>Gregory</surname><given-names>H</given-names></name><name><surname>McWilliam</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>McGhie</surname><given-names>J</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Herzyk</surname><given-names>P</given-names></name><name><surname>Tschannen</surname><given-names>MR</given-names></name><name><surname>Worthey</surname><given-names>E</given-names></name><name><surname>Petty</surname><given-names>R</given-names></name><name><surname>Ballantyne</surname><given-names>B</given-names></name><name><surname>Warner</surname><given-names>J</given-names></name><name><surname>Farrugia</surname><given-names>ME</given-names></name><name><surname>Longman</surname><given-names>C</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><collab>Scottish Myotonic Dystrophy Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>De novo repeat interruptions are associated with reduced somatic instability and mild or absent clinical features in myotonic dystrophy type 1</article-title><source>European Journal of Human Genetics</source><volume>26</volume><fpage>1635</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1038/s41431-018-0156-9</pub-id><pub-id pub-id-type="pmid">29967337</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Jimenez-Moreno</surname><given-names>C</given-names></name><name><surname>Okkersen</surname><given-names>K</given-names></name><name><surname>Wenninger</surname><given-names>S</given-names></name><name><surname>Daidj</surname><given-names>F</given-names></name><name><surname>Hogarth</surname><given-names>F</given-names></name><name><surname>Littleford</surname><given-names>R</given-names></name><name><surname>Gorman</surname><given-names>G</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name><name><surname>Lochmüller</surname><given-names>H</given-names></name><name><surname>van Engelen</surname><given-names>BGM</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><collab>OPTIMISTIC Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort</article-title><source>Neurology</source><volume>93</volume><fpage>e995</fpage><lpage>e1009</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000008056</pub-id><pub-id pub-id-type="pmid">31395669</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>JW</given-names></name><name><surname>Ricker</surname><given-names>K</given-names></name><name><surname>Jacobsen</surname><given-names>JF</given-names></name><name><surname>Rasmussen</surname><given-names>LJ</given-names></name><name><surname>Dick</surname><given-names>KA</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>MC</given-names></name><name><surname>Beilman</surname><given-names>GJ</given-names></name><name><surname>Harrison</surname><given-names>AR</given-names></name><name><surname>Dalton</surname><given-names>JC</given-names></name><name><surname>Ranum</surname><given-names>LPW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum</article-title><source>Neurology</source><volume>60</volume><fpage>657</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000054481.84978.f9</pub-id><pub-id pub-id-type="pmid">12601109</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Coster</surname><given-names>W</given-names></name><name><surname>D’Hert</surname><given-names>S</given-names></name><name><surname>Schultz</surname><given-names>DT</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NanoPack: visualizing and processing long-read sequencing data</article-title><source>Bioinformatics</source><volume>34</volume><fpage>2666</fpage><lpage>2669</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty149</pub-id><pub-id pub-id-type="pmid">29547981</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeJesus-Hernandez</surname><given-names>M</given-names></name><name><surname>Aleff</surname><given-names>RA</given-names></name><name><surname>Jackson</surname><given-names>JL</given-names></name><name><surname>Finch</surname><given-names>NA</given-names></name><name><surname>Baker</surname><given-names>MC</given-names></name><name><surname>Gendron</surname><given-names>TF</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>McLaughlin</surname><given-names>IJ</given-names></name><name><surname>Harting</surname><given-names>JR</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Oskarsson</surname><given-names>B</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Fryer</surname><given-names>JD</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Ebbert</surname><given-names>MTW</given-names></name><name><surname>Wieben</surname><given-names>ED</given-names></name><name><surname>van Blitterswijk</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Long-read targeted sequencing uncovers clinicopathological associations for c9orf72-linked diseases</article-title><source>Brain: A Journal of Neurology</source><volume>144</volume><fpage>1082</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1093/brain/awab006</pub-id><pub-id pub-id-type="pmid">33889947</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depienne</surname><given-names>C</given-names></name><name><surname>Mandel</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>30 years of repeat expansion disorders: what have we learned and what are the remaining challenges?</article-title><source>American Journal of Human Genetics</source><volume>108</volume><fpage>764</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2021.03.011</pub-id><pub-id pub-id-type="pmid">33811808</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ebbert</surname><given-names>MTW</given-names></name><name><surname>Farrugia</surname><given-names>S</given-names></name><name><surname>Sens</surname><given-names>J</given-names></name><name><surname>Jansen-West</surname><given-names>K</given-names></name><name><surname>Gendron</surname><given-names>TF</given-names></name><name><surname>Prudencio</surname><given-names>M</given-names></name><name><surname>McLaughlin</surname><given-names>lanJ</given-names></name><name><surname>Bowman</surname><given-names>B</given-names></name><name><surname>Seetin</surname><given-names>M</given-names></name><name><surname>DeJesus-Hernandez</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>PH</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>van Blitterswijk</surname><given-names>M</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Fryer</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Long-Read Sequencing across the C9orf72 ‘GGGGCC’ Repeat Expansion: Implications for Clinical Use and Genetic Discovery Efforts in Human Disease</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/176651</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>L</given-names></name><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>D’Apice</surname><given-names>MR</given-names></name><name><surname>Peluso</surname><given-names>F</given-names></name><name><surname>Gori</surname><given-names>G</given-names></name><name><surname>Morrone</surname><given-names>A</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><name><surname>Dosa</surname><given-names>L</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification, molecular characterization and segregation analysis of a variant <italic>dmpk</italic> pre-mutation allele in a three-generation italian family</article-title><source>Acta Myologica</source><volume>39</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.36185/2532-1900-002</pub-id><pub-id pub-id-type="pmid">32607474</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>D</given-names></name><name><surname>Nyquist</surname><given-names>K</given-names></name><name><surname>Yabuki</surname><given-names>Y</given-names></name><name><surname>Miyatake</surname><given-names>S</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Hamanaka</surname><given-names>K</given-names></name><name><surname>Saida</surname><given-names>K</given-names></name><name><surname>Koshimizu</surname><given-names>E</given-names></name><name><surname>Tsuchida</surname><given-names>N</given-names></name><name><surname>Fujita</surname><given-names>A</given-names></name><name><surname>Mitsuhashi</surname><given-names>S</given-names></name><name><surname>Ohbo</surname><given-names>K</given-names></name><name><surname>Satake</surname><given-names>Y</given-names></name><name><surname>Sone</surname><given-names>J</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Morihara</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Wenger</surname><given-names>AM</given-names></name><name><surname>Shioda</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Mizuguchi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Father-to-offspring transmission of extremely long NOTCH2NLC repeat expansions with contractions: genetic and epigenetic profiling with long-read sequencing</article-title><source>Clinical Epigenetics</source><volume>13</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/s13148-021-01192-5</pub-id><pub-id pub-id-type="pmid">34774111</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giesselmann</surname><given-names>P</given-names></name><name><surname>Brändl</surname><given-names>B</given-names></name><name><surname>Raimondeau</surname><given-names>E</given-names></name><name><surname>Bowen</surname><given-names>R</given-names></name><name><surname>Rohrandt</surname><given-names>C</given-names></name><name><surname>Tandon</surname><given-names>R</given-names></name><name><surname>Kretzmer</surname><given-names>H</given-names></name><name><surname>Assum</surname><given-names>G</given-names></name><name><surname>Galonska</surname><given-names>C</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Ammerpohl</surname><given-names>O</given-names></name><name><surname>Heron</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>SA</given-names></name><name><surname>Ladewig</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>P</given-names></name><name><surname>Schuldt</surname><given-names>BM</given-names></name><name><surname>Graham</surname><given-names>JE</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Analysis of short tandem repeat expansions and their methylation state with nanopore sequencing</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>1478</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0293-x</pub-id><pub-id pub-id-type="pmid">31740840</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Graham</surname><given-names>JE</given-names></name><name><surname>Raimondeau</surname><given-names>E</given-names></name><name><surname>Bowen</surname><given-names>R</given-names></name><name><surname>Heron</surname><given-names>A</given-names></name><name><surname>Downs</surname><given-names>B</given-names></name><name><surname>Sukumar</surname><given-names>S</given-names></name><name><surname>Sedlazeck</surname><given-names>FJ</given-names></name><name><surname>Timp</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeted nanopore sequencing with cas9-guided adapter ligation</article-title><source>Nature Biotechnology</source><volume>38</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0407-5</pub-id><pub-id pub-id-type="pmid">32042167</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>V</given-names></name><name><surname>Marcolungo</surname><given-names>L</given-names></name><name><surname>Maestri</surname><given-names>S</given-names></name><name><surname>Alfano</surname><given-names>M</given-names></name><name><surname>Lavezzari</surname><given-names>D</given-names></name><name><surname>Iadarola</surname><given-names>B</given-names></name><name><surname>Salviati</surname><given-names>A</given-names></name><name><surname>Mariotti</surname><given-names>B</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>D’Apice</surname><given-names>MR</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><name><surname>Delledonne</surname><given-names>M</given-names></name><name><surname>Rossato</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characterization of FMR1 repeat expansion and intragenic variants by indirect sequence capture</article-title><source>Frontiers in Genetics</source><volume>12</volume><elocation-id>743230</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.743230</pub-id><pub-id pub-id-type="pmid">34646309</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Unusual structures of CCTG repeats and their participation in repeat expansion</article-title><source>Biomolecular Concepts</source><volume>7</volume><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1515/bmc-2016-0024</pub-id><pub-id pub-id-type="pmid">27879482</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafford-Tear</surname><given-names>NJ</given-names></name><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Sadan</surname><given-names>AN</given-names></name><name><surname>Sanchez-Pintado</surname><given-names>B</given-names></name><name><surname>Zarouchlioti</surname><given-names>C</given-names></name><name><surname>Maher</surname><given-names>GJ</given-names></name><name><surname>Liskova</surname><given-names>P</given-names></name><name><surname>Tuft</surname><given-names>SJ</given-names></name><name><surname>Hardcastle</surname><given-names>AJ</given-names></name><name><surname>Clark</surname><given-names>TA</given-names></name><name><surname>Davidson</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CRISPR/cas9-targeted enrichment and long-read sequencing of the fuchs endothelial corneal dystrophy-associated TCF4 triplet repeat</article-title><source>Genetics in Medicine</source><volume>21</volume><fpage>2092</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0453-x</pub-id><pub-id pub-id-type="pmid">30733599</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Höijer</surname><given-names>I</given-names></name><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Clark</surname><given-names>TA</given-names></name><name><surname>Kotturi</surname><given-names>P</given-names></name><name><surname>Dahl</surname><given-names>N</given-names></name><name><surname>Stattin</surname><given-names>EL</given-names></name><name><surname>Bondeson</surname><given-names>ML</given-names></name><name><surname>Feuk</surname><given-names>L</given-names></name><name><surname>Gyllensten</surname><given-names>U</given-names></name><name><surname>Ameur</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Detailed analysis of HTT repeat elements in human blood using targeted amplification-free long-read sequencing</article-title><source>Human Mutation</source><volume>39</volume><fpage>1262</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1002/humu.23580</pub-id><pub-id pub-id-type="pmid">29932473</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holgersen</surname><given-names>EM</given-names></name><name><surname>Gandhi</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Vaz</surname><given-names>B</given-names></name><name><surname>Bogojeski</surname><given-names>J</given-names></name><name><surname>Bugno</surname><given-names>M</given-names></name><name><surname>Shalev</surname><given-names>Z</given-names></name><name><surname>Cheung-Ong</surname><given-names>K</given-names></name><name><surname>Gonçalves</surname><given-names>J</given-names></name><name><surname>O’Hara</surname><given-names>M</given-names></name><name><surname>Kron</surname><given-names>K</given-names></name><name><surname>Verby</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Kakaradov</surname><given-names>B</given-names></name><name><surname>Delong</surname><given-names>A</given-names></name><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Deshwar</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcriptome-wide off-target effects of steric-blocking oligonucleotides</article-title><source>Nucleic Acid Therapeutics</source><volume>31</volume><fpage>392</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1089/nat.2020.0921</pub-id><pub-id pub-id-type="pmid">34388351</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hommelsheim</surname><given-names>CM</given-names></name><name><surname>Frantzeskakis</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Ülker</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PCR amplification of repetitive DNA: A limitation to genome editing technologies and many other applications</article-title><source>Scientific Reports</source><volume>4</volume><elocation-id>5052</elocation-id><pub-id pub-id-type="doi">10.1038/srep05052</pub-id><pub-id pub-id-type="pmid">24852006</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>SV</given-names></name><name><surname>Goodwin</surname><given-names>S</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>McCombie</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Abstract 1360: understanding genetic variation in cancer using targeted nanopore long read sequencing</article-title><source>Cancer Research</source><volume>80</volume><elocation-id>1360</elocation-id><pub-id pub-id-type="doi">10.1158/1538-7445.AM2020-1360</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>SV</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Goodwin</surname><given-names>S</given-names></name><name><surname>McCombie</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ACME: An Affinity-Based Cas9 Mediated Enrichment Method for Targeted Nanopore Sequencing</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.02.03.478550</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamsteeg</surname><given-names>EJ</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Catalli</surname><given-names>C</given-names></name><name><surname>Hertz</surname><given-names>JM</given-names></name><name><surname>Witsch-Baumgartner</surname><given-names>M</given-names></name><name><surname>Buckley</surname><given-names>MF</given-names></name><name><surname>van Engelen</surname><given-names>BGM</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Scheffer</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2</article-title><source>European Journal of Human Genetics</source><volume>20</volume><fpage>1203</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2012.108</pub-id><pub-id pub-id-type="pmid">22643181</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labun</surname><given-names>K</given-names></name><name><surname>Montague</surname><given-names>TG</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name><name><surname>Cleuren</surname><given-names>YNT</given-names></name><name><surname>Tjeldnes</surname><given-names>H</given-names></name><name><surname>Valen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W171</fpage><lpage>W174</lpage></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeflang</surname><given-names>EP</given-names></name><name><surname>Arnheim</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A novel repeat structure at the myotonic dystrophy locus in A 37 repeat allele with unexpectedly high stability</article-title><source>Human Molecular Genetics</source><volume>4</volume><fpage>135</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/hmg/4.1.135</pub-id><pub-id pub-id-type="pmid">7711725</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>M</given-names></name><name><surname>Law</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Chong</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Defining the performance parameters of a rapid screening tool for myotonic dystrophy type 1 based on triplet-primed PCR and melt curve analysis</article-title><source>Expert Review of Molecular Diagnostics</source><volume>16</volume><fpage>1221</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1080/14737159.2016.1241145</pub-id><pub-id pub-id-type="pmid">27665623</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liquori</surname><given-names>CL</given-names></name><name><surname>Ricker</surname><given-names>K</given-names></name><name><surname>Moseley</surname><given-names>ML</given-names></name><name><surname>Jacobsen</surname><given-names>JF</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Naylor</surname><given-names>SL</given-names></name><name><surname>Day</surname><given-names>JW</given-names></name><name><surname>Ranum</surname><given-names>LPW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9</article-title><source>Science</source><volume>293</volume><fpage>864</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1126/science.1062125</pub-id><pub-id pub-id-type="pmid">11486088</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loomis</surname><given-names>EW</given-names></name><name><surname>Eid</surname><given-names>JS</given-names></name><name><surname>Peluso</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Hickey</surname><given-names>L</given-names></name><name><surname>Rank</surname><given-names>D</given-names></name><name><surname>McCalmon</surname><given-names>S</given-names></name><name><surname>Hagerman</surname><given-names>RJ</given-names></name><name><surname>Tassone</surname><given-names>F</given-names></name><name><surname>Hagerman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene</article-title><source>Genome Research</source><volume>23</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1101/gr.141705.112</pub-id><pub-id pub-id-type="pmid">23064752</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Maestri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>MosaicViewer_CNBP</data-title><version designator="95ff074">95ff074</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/MosaicViewer_CNBP/blob/main/Figures/CNBP_left_right_alignment.png">https://github.com/MaestSi/MosaicViewer_CNBP/blob/main/Figures/CNBP_left_right_alignment.png</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Maestri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022a</year><data-title>CharONT2</data-title><version designator="8d27df9">8d27df9</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/CharONT2">https://github.com/MaestSi/CharONT2</ext-link></element-citation></ref><ref id="bib39"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Maestri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022b</year><data-title>MosaicViewer_CNBP</data-title><version designator="f6fb8f2">f6fb8f2</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/MaestSi/MosaicViewer_CNBP">https://github.com/MaestSi/MosaicViewer_CNBP</ext-link></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahyera</surname><given-names>AS</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Halliger-Keller</surname><given-names>B</given-names></name><name><surname>Schrooten</surname><given-names>K</given-names></name><name><surname>Hörner</surname><given-names>EM</given-names></name><name><surname>Rost</surname><given-names>S</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Distribution and structure of DM2 repeat tract alleles in the german population</article-title><source>Frontiers in Neurology</source><volume>9</volume><elocation-id>463</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2018.00463</pub-id><pub-id pub-id-type="pmid">29973908</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangin</surname><given-names>A</given-names></name><name><surname>de Pontual</surname><given-names>L</given-names></name><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Monteil</surname><given-names>L</given-names></name><name><surname>Nizon</surname><given-names>M</given-names></name><name><surname>Boisseau</surname><given-names>P</given-names></name><name><surname>Mercier</surname><given-names>S</given-names></name><name><surname>Ziegle</surname><given-names>J</given-names></name><name><surname>Harting</surname><given-names>J</given-names></name><name><surname>Heiner</surname><given-names>C</given-names></name><name><surname>Gourdon</surname><given-names>G</given-names></name><name><surname>Tomé</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Robust detection of somatic mosaicism and repeat interruptions by long-read targeted sequencing in myotonic dystrophy type 1</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.3390/ijms22052616</pub-id><pub-id pub-id-type="pmid">33807660</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Cardani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Myotonic dystrophy type 2: an update on clinical aspects, genetic and pathomolecular mechanism</article-title><source>Journal of Neuromuscular Diseases</source><volume>2</volume><fpage>S59</fpage><lpage>S71</lpage><pub-id pub-id-type="doi">10.3233/JND-150088</pub-id><pub-id pub-id-type="pmid">27858759</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JN</given-names></name><name><surname>van der Plas</surname><given-names>E</given-names></name><name><surname>Hamilton</surname><given-names>M</given-names></name><name><surname>Koscik</surname><given-names>TR</given-names></name><name><surname>Gutmann</surname><given-names>L</given-names></name><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><name><surname>Nopoulos</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Variant repeats within the DMPK CTG expansion protect function in myotonic dystrophy type 1</article-title><source>Neurology. Genetics</source><volume>6</volume><elocation-id>e504</elocation-id><pub-id pub-id-type="doi">10.1212/NXG.0000000000000504</pub-id><pub-id pub-id-type="pmid">32851192</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsuhashi</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Long-read sequencing for rare human genetic diseases</article-title><source>Journal of Human Genetics</source><volume>65</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/s10038-019-0671-8</pub-id><pub-id pub-id-type="pmid">31558760</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuguchi</surname><given-names>T</given-names></name><name><surname>Toyota</surname><given-names>T</given-names></name><name><surname>Miyatake</surname><given-names>S</given-names></name><name><surname>Mitsuhashi</surname><given-names>S</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Kudo</surname><given-names>Y</given-names></name><name><surname>Kishida</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Tsuburaya</surname><given-names>RS</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Fukuyama</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Koshimizu</surname><given-names>E</given-names></name><name><surname>Tsuchida</surname><given-names>N</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>A</given-names></name><name><surname>Takata</surname><given-names>A</given-names></name><name><surname>Miyake</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Complete sequencing of expanded SAMD12 repeats by long-read sequencing and cas9-mediated enrichment</article-title><source>Brain: A Journal of Neurology</source><volume>144</volume><fpage>1103</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1093/brain/awab021</pub-id><pub-id pub-id-type="pmid">33791773</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammad</surname><given-names>NS</given-names></name><name><surname>Nazli</surname><given-names>R</given-names></name><name><surname>Zafar</surname><given-names>H</given-names></name><name><surname>Fatima</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effects of lipid based multiple micronutrients supplement on the birth outcome of underweight pre-eclamptic women: A randomized clinical trial</article-title><source>Pakistan Journal of Medical Sciences</source><volume>38</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.12669/pjms.38.1.4396</pub-id><pub-id pub-id-type="pmid">35035429</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monckton</surname><given-names>DG</given-names></name><name><surname>Wong</surname><given-names>LJ</given-names></name><name><surname>Ashizawa</surname><given-names>T</given-names></name><name><surname>Caskey</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses</article-title><source>Human Molecular Genetics</source><volume>4</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/hmg/4.1.1</pub-id><pub-id pub-id-type="pmid">7711720</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnese</surname><given-names>F</given-names></name><name><surname>Mondello</surname><given-names>S</given-names></name><name><surname>Wenninger</surname><given-names>S</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2</article-title><source>Journal of Neurology</source><volume>264</volume><fpage>2472</fpage><lpage>2480</lpage><pub-id pub-id-type="doi">10.1007/s00415-017-8653-2</pub-id><pub-id pub-id-type="pmid">29086017</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musova</surname><given-names>Z</given-names></name><name><surname>Mazanec</surname><given-names>R</given-names></name><name><surname>Krepelova</surname><given-names>A</given-names></name><name><surname>Ehler</surname><given-names>E</given-names></name><name><surname>Vales</surname><given-names>J</given-names></name><name><surname>Jaklova</surname><given-names>R</given-names></name><name><surname>Prochazka</surname><given-names>T</given-names></name><name><surname>Koukal</surname><given-names>P</given-names></name><name><surname>Marikova</surname><given-names>T</given-names></name><name><surname>Kraus</surname><given-names>J</given-names></name><name><surname>Havlovicova</surname><given-names>M</given-names></name><name><surname>Sedlacek</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene</article-title><source>American Journal of Medical Genetics. Part A</source><volume>149A</volume><fpage>1365</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.32987</pub-id><pub-id pub-id-type="pmid">19514047</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamori</surname><given-names>M</given-names></name><name><surname>Sobczak</surname><given-names>K</given-names></name><name><surname>Moxley</surname><given-names>RT</given-names></name><name><surname>Thornton</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Scaled-down genetic analysis of myotonic dystrophy type 1 and type 2</article-title><source>Neuromuscular Disorders</source><volume>19</volume><fpage>759</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2009.07.012</pub-id><pub-id pub-id-type="pmid">19713112</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Oxford Nanopore Community</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Oxford Nanopore Technology</article-title><ext-link ext-link-type="uri" xlink:href="https://community.nanoporetech.com/posts/can-ffpe-repair-be-avoided">https://community.nanoporetech.com/posts/can-ffpe-repair-be-avoided</ext-link><date-in-citation iso-8601-date="2022-05-04">May 4, 2022</date-in-citation></element-citation></ref><ref id="bib52"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Oxford Nanopore Community</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Oxford Nanopore Technology</article-title><ext-link ext-link-type="uri" xlink:href="https://community.nanoporetech.com/posts/high-of-unclassified-rea">https://community.nanoporetech.com/posts/high-of-unclassified-rea</ext-link><date-in-citation iso-8601-date="2020-10-31">October 31, 2020</date-in-citation></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>N</given-names></name><name><surname>Rakyan</surname><given-names>V</given-names></name><name><surname>Loose</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>BulkVis: A graphical viewer for oxford nanopore bulk FAST5 files</article-title><source>Bioinformatics</source><volume>35</volume><fpage>2193</fpage><lpage>2198</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty841</pub-id><pub-id pub-id-type="pmid">30462145</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pešović</surname><given-names>J</given-names></name><name><surname>Perić</surname><given-names>S</given-names></name><name><surname>Brkušanin</surname><given-names>M</given-names></name><name><surname>Brajušković</surname><given-names>G</given-names></name><name><surname>Rakočević-Stojanović</surname><given-names>V</given-names></name><name><surname>Savić-Pavićević</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Repeat interruptions modify age at onset in myotonic dystrophy type 1 by stabilizing <italic>dmpk</italic> expansions in somatic cells</article-title><source>Frontiers in Genetics</source><volume>9</volume><elocation-id>601</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2018.00601</pub-id><pub-id pub-id-type="pmid">30546383</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radvansky</surname><given-names>J</given-names></name><name><surname>Ficek</surname><given-names>A</given-names></name><name><surname>Minarik</surname><given-names>G</given-names></name><name><surname>Palffy</surname><given-names>R</given-names></name><name><surname>Kadasi</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Effect of unexpected sequence interruptions to conventional PCR and repeat primed PCR in myotonic dystrophy type 1 testing</article-title><source>Diagnostic Molecular Pathology</source><volume>20</volume><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/PDM.0b013e3181efe290</pub-id><pub-id pub-id-type="pmid">21326039</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radvanszky</surname><given-names>J</given-names></name><name><surname>Surovy</surname><given-names>M</given-names></name><name><surname>Polak</surname><given-names>E</given-names></name><name><surname>Kadasi</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Uninterrupted CCTG tracts in the myotonic dystrophy type 2 associated locus</article-title><source>Neuromuscular Disorders</source><volume>23</volume><fpage>591</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2013.02.013</pub-id><pub-id pub-id-type="pmid">23561036</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Masciullo</surname><given-names>M</given-names></name><name><surname>Pietrobono</surname><given-names>R</given-names></name><name><surname>Conte</surname><given-names>G</given-names></name><name><surname>Modoni</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>MLE</given-names></name><name><surname>Rizzo</surname><given-names>V</given-names></name><name><surname>Pomponi</surname><given-names>MG</given-names></name><name><surname>Tasca</surname><given-names>G</given-names></name><name><surname>Neri</surname><given-names>G</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular, clinical, and muscle studies in myotonic dystrophy type 1 (DM1) associated with novel variant CCG expansions</article-title><source>Journal of Neurology</source><volume>260</volume><fpage>1245</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1007/s00415-012-6779-9</pub-id><pub-id pub-id-type="pmid">23263591</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>L</given-names></name><name><surname>Masciullo</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>MLE</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Leoncini</surname><given-names>E</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expansion size and presence of CCG/CTC/CGG sequence interruptions in the expanded CTG array are independently associated to hypermethylation at the DMPK locus in myotonic dystrophy type 1 (DM1)</article-title><source>Biochimica et Biophysica Acta</source><volume>1852</volume><fpage>2645</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.09.007</pub-id><pub-id pub-id-type="pmid">26391753</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Masciullo</surname><given-names>M</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis</article-title><source>Clinical Genetics</source><volume>92</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1111/cge.12954</pub-id><pub-id pub-id-type="pmid">27991661</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>L</given-names></name><name><surname>Maiorca</surname><given-names>F</given-names></name><name><surname>Centofanti</surname><given-names>F</given-names></name><name><surname>Massa</surname><given-names>R</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expanded [cctg]n repetitions are not associated with abnormal methylation at the cnbp locus in myotonic dystrophy type 2 (dm2) patients</article-title><source>Biochimica et Biophysica Acta. Molecular Basis of Disease</source><volume>1864</volume><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2017.12.037</pub-id><pub-id pub-id-type="pmid">29291944</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergey</surname><given-names>N</given-names></name><name><surname>Koren</surname><given-names>S</given-names></name><name><surname>Rhie</surname><given-names>A</given-names></name><name><surname>Rautiainen</surname><given-names>M</given-names></name><name><surname>Bzikadze</surname><given-names>AV</given-names></name><name><surname>Mikheenko</surname><given-names>A</given-names></name><name><surname>Vollger</surname><given-names>MR</given-names></name><name><surname>Altemose</surname><given-names>N</given-names></name><name><surname>Uralsky</surname><given-names>L</given-names></name><name><surname>Gershman</surname><given-names>A</given-names></name><name><surname>Aganezov</surname><given-names>S</given-names></name><name><surname>Hoyt</surname><given-names>SJ</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Logsdon</surname><given-names>GA</given-names></name><name><surname>Alonge</surname><given-names>M</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name><name><surname>Borchers</surname><given-names>M</given-names></name><name><surname>Bouffard</surname><given-names>GG</given-names></name><name><surname>Brooks</surname><given-names>SY</given-names></name><name><surname>Caldas</surname><given-names>GV</given-names></name><name><surname>Chen</surname><given-names>NC</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Chin</surname><given-names>CS</given-names></name><name><surname>Chow</surname><given-names>W</given-names></name><name><surname>de Lima</surname><given-names>LG</given-names></name><name><surname>Dishuck</surname><given-names>PC</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Dvorkina</surname><given-names>T</given-names></name><name><surname>Fiddes</surname><given-names>IT</given-names></name><name><surname>Formenti</surname><given-names>G</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Fungtammasan</surname><given-names>A</given-names></name><name><surname>Garrison</surname><given-names>E</given-names></name><name><surname>Grady</surname><given-names>PGS</given-names></name><name><surname>Graves-Lindsay</surname><given-names>TA</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name><name><surname>Hansen</surname><given-names>NF</given-names></name><name><surname>Hartley</surname><given-names>GA</given-names></name><name><surname>Haukness</surname><given-names>M</given-names></name><name><surname>Howe</surname><given-names>K</given-names></name><name><surname>Hunkapiller</surname><given-names>MW</given-names></name><name><surname>Jain</surname><given-names>C</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Jarvis</surname><given-names>ED</given-names></name><name><surname>Kerpedjiev</surname><given-names>P</given-names></name><name><surname>Kirsche</surname><given-names>M</given-names></name><name><surname>Kolmogorov</surname><given-names>M</given-names></name><name><surname>Korlach</surname><given-names>J</given-names></name><name><surname>Kremitzki</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Maduro</surname><given-names>VV</given-names></name><name><surname>Marschall</surname><given-names>T</given-names></name><name><surname>McCartney</surname><given-names>AM</given-names></name><name><surname>McDaniel</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>DE</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Myers</surname><given-names>EW</given-names></name><name><surname>Olson</surname><given-names>ND</given-names></name><name><surname>Paten</surname><given-names>B</given-names></name><name><surname>Peluso</surname><given-names>P</given-names></name><name><surname>Pevzner</surname><given-names>PA</given-names></name><name><surname>Porubsky</surname><given-names>D</given-names></name><name><surname>Potapova</surname><given-names>T</given-names></name><name><surname>Rogaev</surname><given-names>EI</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Schneider</surname><given-names>VA</given-names></name><name><surname>Sedlazeck</surname><given-names>FJ</given-names></name><name><surname>Shafin</surname><given-names>K</given-names></name><name><surname>Shew</surname><given-names>CJ</given-names></name><name><surname>Shumate</surname><given-names>A</given-names></name><name><surname>Sims</surname><given-names>Y</given-names></name><name><surname>Smit</surname><given-names>AFA</given-names></name><name><surname>Soto</surname><given-names>DC</given-names></name><name><surname>Sović</surname><given-names>I</given-names></name><name><surname>Storer</surname><given-names>JM</given-names></name><name><surname>Streets</surname><given-names>A</given-names></name><name><surname>Sullivan</surname><given-names>BA</given-names></name><name><surname>Thibaud-Nissen</surname><given-names>F</given-names></name><name><surname>Torrance</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Walenz</surname><given-names>BP</given-names></name><name><surname>Wenger</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>JMD</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>SM</given-names></name><name><surname>Young</surname><given-names>AC</given-names></name><name><surname>Zarate</surname><given-names>S</given-names></name><name><surname>Surti</surname><given-names>U</given-names></name><name><surname>McCoy</surname><given-names>RC</given-names></name><name><surname>Dennis</surname><given-names>MY</given-names></name><name><surname>Alexandrov</surname><given-names>IA</given-names></name><name><surname>Gerton</surname><given-names>JL</given-names></name><name><surname>O’Neill</surname><given-names>RJ</given-names></name><name><surname>Timp</surname><given-names>W</given-names></name><name><surname>Zook</surname><given-names>JM</given-names></name><name><surname>Schatz</surname><given-names>MC</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Miga</surname><given-names>KH</given-names></name><name><surname>Phillippy</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The complete sequence of a human genome</article-title><source>Science</source><volume>376</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1126/science.abj6987</pub-id><pub-id pub-id-type="pmid">35357919</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siena</surname><given-names>Cd</given-names></name><name><surname>Cardani</surname><given-names>R</given-names></name><name><surname>Brigonzi</surname><given-names>E</given-names></name><name><surname>Bosè</surname><given-names>F</given-names></name><name><surname>Fossati</surname><given-names>B</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>E</given-names></name><name><surname>Valaperta</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Incidence of amplification failure in DMPK allele due to allelic dropout event in a diagnostic laboratory</article-title><source>Clinica Chimica Acta; International Journal of Clinical Chemistry</source><volume>484</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2018.05.040</pub-id><pub-id pub-id-type="pmid">29803895</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sone</surname><given-names>J</given-names></name><name><surname>Mitsuhashi</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>A</given-names></name><name><surname>Mizuguchi</surname><given-names>T</given-names></name><name><surname>Hamanaka</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Koike</surname><given-names>H</given-names></name><name><surname>Hashiguchi</surname><given-names>A</given-names></name><name><surname>Takashima</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>H</given-names></name><name><surname>Kohno</surname><given-names>Y</given-names></name><name><surname>Takiyama</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Koyano</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Kawamoto</surname><given-names>M</given-names></name><name><surname>Kohara</surname><given-names>N</given-names></name><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Ieda</surname><given-names>T</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name><name><surname>Kokubun</surname><given-names>N</given-names></name><name><surname>Tsuboi</surname><given-names>Y</given-names></name><name><surname>Katoh</surname><given-names>K</given-names></name><name><surname>Kino</surname><given-names>Y</given-names></name><name><surname>Katsuno</surname><given-names>M</given-names></name><name><surname>Iwasaki</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Suzuki</surname><given-names>IK</given-names></name><name><surname>Frith</surname><given-names>MC</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Sobue</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease</article-title><source>Nature Genetics</source><volume>51</volume><fpage>1215</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0459-y</pub-id><pub-id pub-id-type="pmid">31332381</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevanovski</surname><given-names>I</given-names></name><name><surname>Chintalaphani</surname><given-names>SR</given-names></name><name><surname>Gamaarachchi</surname><given-names>H</given-names></name><name><surname>Ferguson</surname><given-names>JM</given-names></name><name><surname>Pineda</surname><given-names>SS</given-names></name><name><surname>Scriba</surname><given-names>CK</given-names></name><name><surname>Tchan</surname><given-names>M</given-names></name><name><surname>Fung</surname><given-names>V</given-names></name><name><surname>Ng</surname><given-names>K</given-names></name><name><surname>Cortese</surname><given-names>A</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Dobson-Stone</surname><given-names>C</given-names></name><name><surname>Fitzpatrick</surname><given-names>L</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Ravenscroft</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>MR</given-names></name><name><surname>Laing</surname><given-names>NG</given-names></name><name><surname>Fellner</surname><given-names>A</given-names></name><name><surname>Kennerson</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>KR</given-names></name><name><surname>Deveson</surname><given-names>IW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabm5386</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abm5386</pub-id><pub-id pub-id-type="pmid">35245110</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Myotonic dystrophy</article-title><source>Neurologic Clinics</source><volume>32</volume><fpage>705</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.ncl.2014.04.011</pub-id><pub-id pub-id-type="pmid">25037086</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomé</surname><given-names>S</given-names></name><name><surname>Dandelot</surname><given-names>E</given-names></name><name><surname>Dogan</surname><given-names>C</given-names></name><name><surname>Bertrand</surname><given-names>A</given-names></name><name><surname>Geneviève</surname><given-names>D</given-names></name><name><surname>Péréon</surname><given-names>Y</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Bonnefont</surname><given-names>JP</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Gourdon</surname><given-names>G</given-names></name><collab>DM contraction study group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Unusual association of a unique CAG interruption in 5’ of DM1 CTG repeats with intergenerational contractions and low somatic mosaicism</article-title><source>Human Mutation</source><volume>39</volume><fpage>970</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1002/humu.23531</pub-id><pub-id pub-id-type="pmid">29664219</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Greenberg</surname><given-names>D</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Höijer</surname><given-names>I</given-names></name><name><surname>Ameur</surname><given-names>A</given-names></name><name><surname>Strahl</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>E</given-names></name><name><surname>Jonasson</surname><given-names>I</given-names></name><name><surname>Mouro Pinto</surname><given-names>R</given-names></name><name><surname>Wheeler</surname><given-names>VC</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Gyllensten</surname><given-names>U</given-names></name><name><surname>Sebra</surname><given-names>R</given-names></name><name><surname>Korlach</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Amplification-Free, CRISPR-Cas9 Targeted Enrichment and SMRT Sequencing of Repeat-Expansion Disease Causative Genomic Regions</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/203919</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name><name><surname>Thornton</surname><given-names>C</given-names></name><name><surname>Ranum</surname><given-names>L</given-names></name><name><surname>Day</surname><given-names>J</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Ricker</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd workshop, 14-16 february 2003, naarden, the netherlands</article-title><source>Neuromuscular Disorders</source><volume>13</volume><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/s0960-8966(03)00092-0</pub-id><pub-id pub-id-type="pmid">12921797</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>AD</given-names></name><name><surname>Sasani</surname><given-names>TA</given-names></name><name><surname>Swanier</surname><given-names>J</given-names></name><name><surname>Gates</surname><given-names>BL</given-names></name><name><surname>Greenland</surname><given-names>J</given-names></name><name><surname>Pedersen</surname><given-names>BS</given-names></name><name><surname>Varley</surname><given-names>KE</given-names></name><name><surname>Quinlan</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CaBagE: A cas9-based background elimination strategy for targeted, long-read DNA sequencing</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0241253</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0241253</pub-id><pub-id pub-id-type="pmid">33830997</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieben</surname><given-names>ED</given-names></name><name><surname>Aleff</surname><given-names>RA</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name><name><surname>Sarangi</surname><given-names>V</given-names></name><name><surname>Bowman</surname><given-names>B</given-names></name><name><surname>McLaughlin</surname><given-names>IJ</given-names></name><name><surname>Mills</surname><given-names>JR</given-names></name><name><surname>Butz</surname><given-names>ML</given-names></name><name><surname>Highsmith</surname><given-names>EW</given-names></name><name><surname>Ida</surname><given-names>CM</given-names></name><name><surname>Ekholm</surname><given-names>JM</given-names></name><name><surname>Baratz</surname><given-names>KH</given-names></name><name><surname>Fautsch</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Amplification-free long-read sequencing of TCF4 expanded trinucleotide repeats in fuchs endothelial corneal dystrophy</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0219446</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0219446</pub-id><pub-id pub-id-type="pmid">31276570</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80229.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Murim</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.12.491603" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.12.491603"/></front-stub><body><p>The study utilized a long-read sequencing to correctly assess expanded alleles in DM2 patients and has technical and diagnostic value. We anticipate more valuable approaches like this in the near future.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80229.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Moon</surname><given-names>Jangsup</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01z4nnt86</institution-id><institution>Seoul National University Hospital</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.12.491603">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.12.491603v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Characterization of full-length <italic>CNBP</italic> expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Murim Choi as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Martin Pollak as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Jangsup Moon (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The reviewers think that this is an interesting study in which the authors conducted Cas9-mediated enrichment and nanopore sequencing to characterize the full-length CNBP expanded alleles in nine myotonic dystrophy type 2 (DM2) patients. However, several improvements are required to warrant publication in <italic>eLife</italic>. The reviewers were concerned with the following issues:</p><p>(1) Novelty and clinical utility of the study needs to be emphasized.</p><p>(2) More details on technical aspects.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Clear visualization of repeat status and how it is altered in each patient would help readers understand the results, including a pedigree of the familial cases.</p><p>It would help to assess the practical advantages of their method: is it cheaper and faster than the conventional method?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Overall, this study was well performed and the manuscript was well written, however, there are several points that need to be clarified by the authors.</p><p>1. Regarding the (TCTG)n repeats at the 3'end</p><p>The percentage of reads carrying the TCTG motif is demonstrated in Table 2, but the fact that the existence of mosaicism can be assumed from this data is not sufficiently explained in the result section. Please include some explanation about the mosaicism.</p><p>Is there any possibility that the result shown in Figure 3 is caused by damaged (fragmented) DNA rather than mosaicism? Please explain.</p><p>2. In the method section, regarding Cas9 sequencing</p><p>Is there any reason why two different DNA extraction methods have been used in patients?</p><p>Is there any basis for determining which method to apply to each patient? Please explain.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80229.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers think that this is an interesting study in which the authors conducted Cas9-mediated enrichment and nanopore sequencing to characterize the full-length CNBP expanded alleles in nine myotonic dystrophy type 2 (DM2) patients. However, several improvements are required to warrant publication in eLife. The reviewers were concerned with the following issues:</p><p>(1) Novelty and clinical utility of the study needs to be emphasized.</p></disp-quote><p>The novelty and clinical utility of the study have been now better emphasized in the Discussion section. Please refer for more details to replies to point 1, 2 and 6 given to reviewer 1.</p><disp-quote content-type="editor-comment"><p>(2) More details on technical aspects.</p></disp-quote><p>More details on technical aspects have been now provided both in the Results and in the Material and Method section. Please refer for more details to replies to point 3 and 5 given to reviewer 1 and to replies to point 1 and 2 given to reviewer 2.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Clear visualization of repeat status and how it is altered in each patient would help readers understand the results, including a pedigree of the familial cases.</p></disp-quote><p>The repeat status identified by Cas9-mediated sequencing has been now reported more clearly in Table 3. For clarity, the altered quadruplet motifs of each patient have been highlighted with different colours. For the familial cases, we have also included additional figures showing the pedigree (Figure 1—figure supplement 1) and a magnification of reads aligned at the microsatellite locus (Figure 3—figure supplement 2), to show that all family members carry the same motif structure at the repeat 5’-end.</p><disp-quote content-type="editor-comment"><p>It would help to assess the practical advantages of their method: is it cheaper and faster than the conventional method?</p></disp-quote><p>Although potentially applicable for the clinical diagnostics, to date the costs of Cas9-mediated sequencing for a single patient are relatively high and not comparable with the PCR-based approaches used in the routine of the DM2 molecular diagnostics. Nevertheless, the method represents a step forward in DM2 diagnosis, because it will allow to unravel those molecular aspects invisible to conventional methods and thus complement them. In particular, it will help to solve unusual large and complex (CCTG)n expansions not detectable with conventional methods and to identify non-canonical repetitive motifs and sequence interruptions, not visible with other approaches. Taken together, this information will allow more precise correlation between the length and composition of DM2 expansion and the clinical phenotype. In a next future, further evolution of ONT chemistry and the optimization of multiplexing strategies are expected to drastically decrease the cost for the analysis, making the Cas9-mediated sequencing more easily accessible in clinical practice. In terms of turn-around-time, this is already compatible with the diagnostic settings and comparable to conventional methods (1-2 days).</p><p>Considerations related to the clinical utility of the approach have been now included in the “Discussion” section (lines 301-307 and lines 427-435).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Overall, this study was well performed and the manuscript was well written, however, there are several points that need to be clarified by the authors.</p><p>1. Regarding the (TCTG)n repeats at the 3'end</p><p>The percentage of reads carrying the TCTG motif is demonstrated in Table 2, but the fact that the existence of mosaicism can be assumed from this data is not sufficiently explained in the result section. Please include some explanation about the mosaicism.</p><p>Is there any possibility that the result shown in Figure 3 is caused by damaged (fragmented) DNA rather than mosaicism? Please explain.</p></disp-quote><p>We recognize that the result section describing the observed mosaicism was too concise. To address this reviewer’s concern, we have now included a more detailed description and provided an example helping the interpretation of results shown in Table 3 and Figure 3 and Figure 3—figure supplement 1 (see Results, Lines 215-219). For the analysis of expanded microsatellites, we considered only those reads containing at least 600bp up/down-stream the <italic>CNBP</italic> microsatellite, and thus comprising the repeat entirely; we therefore exclude that the extreme variability in molecule length could be ascribed to the analysis of fragmented DNA molecules. This has been now better specified both in the Results (Lines 217-219) and in the Material and Method section (Lines 534-538).</p><disp-quote content-type="editor-comment"><p>2. In the method section, regarding Cas9 sequencing</p><p>Is there any reason why two different DNA extraction methods have been used in patients?</p><p>Is there any basis for determining which method to apply to each patient? Please explain.</p></disp-quote><p>Available blood samples of DM2 patients derived from a retrospective cohort and it was stored in our biobank since long time (years). Moreover, the collection and storage of these samples were not conducted with the required precautions for HMW DNA extraction, as preferable for ONT sequencing. Therefore, we could obtain DNA with a kit designed for HMW extraction (Nanobind CBB Big DNA HMW Kit, Circulomics) only from a fraction of patients. When this kit failed, likely due to the presence of partially degraded DNA, we succeeded in the extraction with a more traditional extraction kit (NucleoSpin Blood L Kit, Macherey-Nagel), also yielding long DNA molecules but retaining even shorter ones and thus facilitating the recovery. This aspect has been now clarified in the Material and Method section (lines 483-489).</p><p>References</p><p>Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003 Feb 25;60(4):657-64. doi: 10.1212/01.wnl.0000054481.84978.f9. PMID: 12601109.</p><p>Mitsuhashi S, Frith MC, Matsumoto N. Genome-wide survey of tandem repeats by nanopore sequencing shows that disease-associated repeats are more polymorphic in the general population. BMC Med Genomics. 2021 Jan 7;14(1):17. doi: 10.1186/s12920-020-00853-3. PMID: 33413375; PMCID: PMC7791882.</p><p>Shruti V Iyer, Melissa Kramer, Sara Goodwin, W. Richard McCombie. ACME: an Affinity-based Cas9 Mediated Enrichment method for targeted nanopore sequencing. bioRxiv 2022.02.03.478550; doi: https://doi.org/10.1101/2022.02.03.478550</p><p>Stevanovski I, Chintalaphani SR, Gamaarachchi H, Ferguson JM, Pineda SS, Scriba CK, Tchan M, Fung V, Ng K, Cortese A, Houlden H, Dobson-Stone C, Fitzpatrick L, Halliday G, Ravenscroft G, Davis MR, Laing NG, Fellner A, Kennerson M, Kumar KR, Deveson IW. Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. Sci Adv. 2022 Mar 4;8(9):eabm5386. doi: 10.1126/sciadv.abm5386. Epub 2022 Mar 4. PMID: 35245110; PMCID: PMC8896783.</p><p>Vanacore N, Rastelli E, Antonini G, Bianchi ML, Botta A, Bucci E, Casali C, Costanzi-Porrini S, Giacanelli M, Gibellini M, Modoni A, Novelli G, Pennisi EM, Petrucci A, Piantadosi C, Silvestri G, Terracciano C, Massa R. An Age-Standardized Prevalence Estimate and a Sex and Age Distribution of Myotonic Dystrophy Types 1 and 2 in the Rome Province, Italy. Neuroepidemiology. 2016;46(3):191-7. doi: 10.1159/000444018. Epub 2016 Feb 17. PMID: 26882032.</p></body></sub-article></article>